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Résumé 
 
La dihydrofolate réductase humaine (DHFRh) est une enzyme essentielle à la 
prolifération cellulaire, ce qui en fait une cible de choix pour le traitement de différents 
cancers. À cet effet, plusieurs inhibiteurs spécifiques de la DHFRh, les antifolates, ont été 
mis au point : le méthotrexate (MTX) et le pemetrexed (PMTX) en sont de bons 
exemples. Malgré l’efficacité clinique certaine de ces antifolates, le développement de 
nouveaux traitements s’avère nécessaire afin de réduire les effets secondaires liés à leur 
utilisation. Enfin, dans l’optique d’orienter la synthèse de nouveaux composés inhibiteurs 
des DHFRh, une meilleure connaissance des interactions entre les antifolates et leur 
enzyme cible est primordiale. 
À l’aide de l’évolution dirigée, il a été possible d’identifier des mutants de la 
DHFRh pour lesquels l’affinité envers des antifolates cliniquement actifs se voyait 
modifiée. La mutagenèse dite de saturation a été utilisée afin de générer des banques de 
mutants présentant une diversité génétique au niveau des résidus du site actif de l’enzyme 
d’intérêt. De plus, une nouvelle méthode de criblage a été mise au point, laquelle s’est 
avérée efficace pour départager les mutations ayant entrainé une résistance aux 
antifolates et/ou un maintient de l’activité enzymatique envers son substrat natif, soient 
les phénotypes d’activité. La méthode de criblage consiste dans un premier temps en une 
sélection bactérienne à haut débit, puis dans un second temps en un criblage sur plaques 
permettant d’identifier les meilleurs candidats. Plusieurs mutants actifs de la DHFRh, 
résistants aux antifolates, ont ainsi pu être identifiés et caractérisés lors d’études de 
cinétique enzymatique (kcat et IC50). Sur la base de ces résultats cinétiques, de la 
modélisation moléculaire et des données structurales de la littérature, une étude structure-
activité a été effectuée. En regardant quelles mutations ont les effets les plus significatif 
sur la liaison, nous avons commencé à construire un carte moléculaire des contacts 
impliqués dans la liaison des ligands. Enfin, des connaissances supplémentaires sur les 
propriétés spécifiques de liaison ont put être acquises en variant l’inhibiteur testé, 
permettant ainsi une meilleure compréhension du phénomène de discrimination du 
ligand.  
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Mots clés : dihydrofolate réductases humaine, méthotrexate, pemetrexed, résistance aux 
médicaments, mutagenèse, évolution dirigée, criblage à haut débit, relation structure-
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Abstract 
Human dihydrofolate reductase (hDHFR) is an essential enzyme for cellular 
proliferation and it has long been the target of antifolate drugs for the treatment of 
various types of cancer. Despite the clinical effectiveness of current antifolate treatments, 
new drugs are required to reduce the side-effects associated with their use. An essential 
requirement for design of new antifolates is a better understanding of how these drugs 
interact with their targets.  
We applied directed evolution to identify mutant hDHFR variants with modified 
binding to some clinically relevant antifolates. A saturation mutagenesis approach was 
used to create genetic diversity at active-site residues of hDHFR and a new, efficient 
screening strategy was developed to identify the amino acids that preserved native 
activity and/or conferred antifolate resistance. The screening method consists in a high-
throughput first-tier bacterial selection coupled with a second-tier in vitro assay that 
allows for rapid detection of the best variants among the leads, according to user-defined 
parameters. Many active, antifolate-resistant mutants of hDHFR were identified. 
Moreover, the approach has proven efficient in rapidly assessing kinetic (kcat) and 
inhibition parameters of the hDHFR variants (IC50). Structure-function relationship 
analysis based on kinetic investigation, available structural and functional data as well as 
modeling were performed. By monitoring which mutations have the greatest effect on 
binding, we have begun to build a molecular picture of the contacts involved in drug 
binding. By varying the drugs we test against, we gain a better understanding of the 
specific binding properties that determine ligand discrimination.  
 
Keywords : human dihydrofolate reductase, methotrexate, pemetrexed, drug-resistance, 
saturation and combinatorial mutagenesis, directed evolution, high-throughput screening, 
structure-function relationship, enzyme kinetics, molecular modeling. 
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Chapter 1 - Introduction 
 
Section 1.0 - Folate metabolism  
Folic acid derivatives are essential coenzymes required by all living organisms in 
the de novo synthesis of thymidylate and purines, the building blocks for nucleic acid 
synthesis (figure 1.1, 1.1a and 1.1b) [1]. Thus, these cofactors have a crucial role during 
cell proliferation. Folate derivatives, in the form of a series of tetrahydrofolate (THF) 
compounds, act as cofactors in a number of one-carbon-transfer reactions within these 
biosyntheses, and they are also involved in homocysteine methylation and glycine and 
serine interconversion (figure 1.1) [1]. THF is obligatorily produced from 7,8-
dihydrofolate (DHF) by the enzyme dihydrofolate reductase (DHFR) [2]. Enzymes 
depending on THF cofactors include thymidylate synthase (TS), glycinamide 
ribonucleotide formyl transferase (GARFT) and aminoimidazole carboxamide formyl 
transferase (AICARFT). TS uses the cofactor 5,10-methylene tetrahydrofolate to convert 
deoxyuridylate (dUMP) into thymidylate (dTMP)(figure 1.1a) [2]. GARFT and 
AICARFT add carbon 8 and 2, respectively to the ring structure of purine using N10-
formyl tetrahydrofolate as cofactor (figure 1.1b)[2]. 
Folates are mainly transported into cells by two energy-dependent carrier proteins: 
the reduced folate carrier (RFC) [3], which is bi-directional, and the folate binding 
protein (FBP) [4].  Intracellular concentration of folates is constantly maintained between 
1 and 10 μM, compared to a plasma concentration  of 10 to 30 nM [5]. This intracellular 
accumulation is mediated by polyglutamation. The enzyme folypolyglutamate synthase 
(FPGS) [1] adds 5 to 8 glutamate residues to the glutamate tail of folates via peptidic 
bonds. The enzyme γ-glutamyl hydrolase (GGH) [6], instead, removes terminal 
glutamate groups. Glutamation makes folates more polar and it can increase the affinity 
of folates for their target enzymes. The extent of polyglutamation of folates depends on 
their affinity for these two cytosolic enzymes. 
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Folate metabolism in cells is a dynamic process in which the levels of THF-
cofactors and DHF vary with the intracellular activities. In resting cells (not in S-phase), 
DHFR activity is much higher than TS activity. This maintains cellular DHF at very low 
levels, in the range of the low nM [1, 7]. As the KMDHF for DHFR is  < 75 nM [8], only a 
fraction of DHFR activity (< 5%) is sufficient to sustain normal rates of THF synthesis 
[1].  Inhibition of folate-dependent enzymes in actively proliferating cells leads to arrest 
of the synthesis of DNA precursors. Thus, these enzymes are major drug targets for the 
treatment of cancer diseases [5], as well as fungal [9, 10], microbial [11] and parasitic 
[12] infections that are dependent on cellular proliferation. 
Section 1.1 - Dihyrofolate reductase  
Dihydrofolate reductase (tetrahydrofolate: NADP+ oxidoreductase; E.C.C. 
1.5.1.3) is a cytosolic enzyme that catalyzes the NADPH-dependent reduction of 7,8-
dihydrofolate (DHF) to 5,6,7,8-tetrahydrofolate (THF) in all living organisms (figure 
1.2A) [1]. Vertebrate DHFRs also catalyse the reduction of folate (FOL) to DHF, at about 
one tenth the rate of DHF reduction (figure 1.2A) [1].  
DHFR has attracted the attention of protein chemists and of molecular biologists 
as a model in many structural, kinetic and mutagenic studies due not only to its clinical 
relevance as a pharmacological target, but also to its small size (18-22 kDa), stability and 
relative ease of producing the recombinant enzyme. In fact, eukaryotic DHFRs are small 
monomeric proteins which does not require any post-translational modification and thus, 
can be easily expressed in heterologous bacterial hosts for ease of manipulation [13]. The 
human dhfr gene, for example, was cloned and expressed in E. coli in 1988 [14], and 
since then, extensive investigations of this enzyme have been performed.  
Section 1.1.1 - Reaction mechanism  
For the reduction of DHF to THF the hydride is transferred from the C4 of 
NADPH to the C6 of DHF, and this transfer is critically dependent on the distance 
between the two carbon atoms (optimal distance 2.6 Å) and the relative orientation of the 
NADPH nicotinamide ring and the DHF pteridine ring (figure 1.2B) [15]. Different 
studies [16-18] suggest that protonation of N5 in the transition state, which either 
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immediately precedes or is concerted with hydride transfer to the C6, promotes hydride 
transfer by delocalizing a positive charge to C6. Residue 30 is the catalytic active-site 
residue, which mediates, through intervening water molecules, the proton transfer 
component of the reduction [15, 19]. A similar mechanism has been proposed for the 
DHFR-dependent reduction of FOL to DHF, where protonation of N8 could be promoted 
by formation of a H-bond with the backbone carbonyl of Ile7, as observed in the crystal 
of the binary complex of human DHFR with 5-deazafolate, a tight-binding inhibitor of 
DHFR very similar to DHF [18]. 
Section 1.1.2 - Vertebrate and bacterial DHFRs: differences and 
similarities 
Vertebrate DHFRs are highly homologous (72-89% sequence identities for 
DHFRs from chicken, mouse, bovine and human), but only ~25% identity is observed 
between animal and bacterial sequences or between different species of bacteria (figure 
1.3) [20]. Despite the low sequence identity between bacterial and vertebrate DHFRs, 
structural analysis of DHFRs from different species has shown that the overall tertiary 
structures of these enzymes are very similar to one another (figure 1.3) [21, 22].  
Notwithstanding the great structural similarity observed, this group of enzymes 
exhibits considerable species-to-species variability in sensitivity to different inhibitors 
[21]. E. coli DHFR (ecDHFR), for example, is 12000-fold more sensitive to the antifolate 
trimethoprim (TMP) than the human variant (hDHFR). Although active site residues are 
generally conserved, some differences exist and could partly explain this variability. 
Leu28 in E. coli DHFR, for example, which was reported to establish a major contact 
with the trimethoxybenzyl moiety of TMP [23], corresponds to Phe31 in hDHFR. 
However, mutation of Phe31 to Leu in hDHFR, did not increase TMP binding 
significantly, indicating that this residue was not the sole determinant of species 
selectivity of TMP [24].  Differences in active-site cavity were also reported to contribute 
to the observed differences in specificity [22, 25]. Despite extensive investigation, the 
structural basis for the various modes of binding in DHFR from different species still 
remains to be fully understood and it represents a crucial point for the design of species-
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specific inhibitors [26]. Jordan Volpato, PhD student in the research group of Prof. Joelle 
Pelletier, has recently conducted a detailed review regarding this subject [27].  
Section 1.1.3 - Human dihydrofolate reductase 
Human DHFR (hDHFR) is a monomeric enzyme of 186 amino acids (21544 Da). 
The polypeptide backbone of hDHFR is folded into an eight-stranded twisted β-sheet, 
consisting of 7 parallel strands and one anti-parallel strand leading to the carboxyl 
terminus. Five α-helices and loops provide connectivity within the sheets (figure 1.4) 
[28]. Residues 21-26 (sequence DLPWPP) form two turns of a polyproline helix (left 
handed, typeII) (figure 1.4) [28].   
Section 1.1.3.1 – Folate binding site 
The structures of many complexes of hDHFR with cofactors, substrate or 
inhibitors have been determined both by X-ray diffraction methods [18, 22, 28, 29] and 
by NMR [30, 31].  Of the two substrates of hDHFR, only FOL has been crystallized in 
the binding cavity of the enzyme (in absence of the cofactor NADPH) (figure 1.5A) [18, 
28]. FOL is a relatively stable molecule while DHF is readily oxidized to FOL, and 
therefore not suitable for protein co-cristallization [18]. The folate binding site is 
composed by residues in strands βA and βE, residues 61-70 and residues belonging to the 
left-handed polyproline helix and helices αB, αC [18].  
The folate and folate-like molecules consist of polar pteridine and L-glutamate 
extremities, linked by a p-aminobenzoyl group (p-ABA) (figure 1.7). The active site of 
DHFR is a ~15 Å hydrophobic pocket in which the only polar side chain is the carbonyl 
of Glu30 [15]. The pteridine moiety of substrates and inhibitors binds nearly 
perpendicular to the benzoyl ring in the bottom of the hydrophobic pocket, with the 
benzoyl-glutamate side chain directed towards the surface of the protein. NADPH binds 
in an extended conformation with the reduced nicotinamide ring inserted into the active 
site pocket and the rest of the molecule along the surface of the protein. The nicotinamide 
ring is situated about 2.5 Å from the folate pteridine ring, with which it forms stacking 
interactions [18].  
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Table 1.1 lists the residues of hDHFR that directly interact with DHF. The 2-
amino group, N3 and O4 of the pteridine moiety of folate interact specifically with 
residues Glu30, Thr136 and Trp24 by direct or water mediated H-bonds. Phe34 is within 
the van der Waals distance of the pteridine moiety. No specific interactions involve 
nitrogens N1, N5, N8 and N10 of folate. In DHF, which has a hydrogen atom attached to 
N8, a hydrogen bond between N8 and the carbonyl oxygen of Ile7 is likely to form, 
whereas an equivalent hydrogen bond to N8 of folate is likely to be formed only in the 
transition state [18].  
The p-ABA moiety of folate is within van der Waals distance of the side chains of 
Phe31, Phe34, Ile60, Pro61 and Leu67. Moreover, the carbonyl oxygen of p-ABA forms 
a H-bond with the amide nitrogen of the Asn64 side chain [28]. 
 The α-carboxylate portion of the glutamate fragment forms a salt bridge with the 
guanidinium of the conserved Arg70. Gln35 is in proximity to both the α-carboxylate and 
γ-carboxylate portions of DHF. The γ-carboxylate can form a H-bond mediated by a 
water molecule with the carbonyl oxygen of R28. However, this portion has a high B 
factor and the bond with R28 is not observed in all resolved structures, probably 
indicating that it is weak [18].  
 
Section 1.2 – Antifolates  
Antifolates constitute a large family of compounds which compete with folate 
derivatives for the binding to folate-dependent enzymes involved in nucleotide 
biosynthesis. Due to the role of their target enzymes in cellular proliferation, antifolates 
are used for the treatment of a broad range of proliferative diseases. Treatment of 
bacterial and parasitic infection is based on species-selectivities of some of these 
compounds. Trimethoprim (TMP), for example, is selective towards bacterial DHFRs 
[26] while pyrimethamine (PYR) towards malaria parasite DHFRs [26]. 
The importance of DHFR in bacterial, parasitic and cancer chemotherapy arises 
from its function in maintaining the pool of THF. Inhibition of DHFR leads to arrest of 
DHF recycling, and thus causes inhibition of cell growth and eventually cell death. It 
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should be noted that THF is regenerated in most one-carbon transfer reactions, with the 
exception of TS-catalyzed dTMP synthesis (figure 1.1). Therefore, in cells not actively 
synthesizing thymidylate and DNA, inhibition of DHFR does not result in any particular 
effect.  
 In 1947, pteroylaspartic acid, an antagonist of pteroyl glutamic acid (folic acid), 
was proved to interfere with folic acid metabolism and the normal growth of cells in in 
vivo test with both chicken and rats [32], and suggested  that folic acid antagonists might 
be of value in patients with rapidly growing malignant disease. In 1948 the antifolate 
aminopterin (figure 1.7) was shown to be effective in children affected by acute leukemia 
at the terminal stage of the disease, marking the advent of cancer chemotherapy [33]. 
Soon after, aminopterin was replaced by the more effective and less toxic amethopterin 
(later named methotrexate (MTX), figure 1.7), which was approved by FDA in 1953. 
Since then, MTX has been the major antifolate used in cancer therapy [34].   
Both aminopterin and MTX are strong competitive inhibitors of DHFR (for 
hDHFR, Ki aminopterin = 2 pM [35] and Ki MTX = 3.4 pM [13]).  
Section 1.2.1 - Methotrexate 
Methotrexate (MTX; 8-amino,10-methyl-pteryolglutamic acid) is a slow, tight 
binding, reversible  inhibitor of the human enzyme dihydrofolate reductase (hDHFR) [13, 
36]. The inhibition constant of hDHFR for MTX is of 3.4 pM [13, 36, 37]. MTX also 
inhibits human GARFT and human AICARFT, but the Ki values for the pentaglutamate 
forms of these enzymes (potency of DHFR inhibition depends on the polyglutamation 
status of the molecules) are of 2500 nM and 56 nM, respectively [5]. These kinetic data 
suggest that the main intracellular target is DHFR [5]. 
MTX shows high affinity for a wide range of DHFRs from different species 
(bacterial, parasitic, vertebrate). Due to its lack of specificity, it is mostly applied for the 
treatment of human proliferative diseases, both malignant (carcinoma, metastatic breast 
cancer, bladder cancer, lymphoma)[5] and not-malignant (rheumatoid arthritis [38], 
psoriasis [39] and graft versus host disease [40]). Despite the continuous discovery of 
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newer drugs, MTX often remains a component of the newer combination treatments [5, 
34].  
The kinetics of MTX binding to hDHFR was described extensively by Appleman 
et al. [13]. MTX binds rapidly and tightly (kon = 1.0 x 10-8 M-1 s-1; koff  < 1 s-1; koff/kon = 
210 pM), independently of the presence or absence of  NADPH already bound to the 
enzyme [13]. The initial association of MTX to hDHFR is followed by some kind of 
conformational change of the complex, which increases the overall binding of 60-fold, 
leading to a Ki of 3.4 pM [13]. The authors also demonstrated that MTX polyglutamation, 
differently from what happens for TS, GARFT and AICARFT [5], does not affect 
binding to hDHFR.  Like folate, MTX is transported into cells by both RFC and FBP [5, 
41, 42]. 
Binding of MTX to hDHFR has been studied using X-ray crystallography [22, 43] 
(table 1.1 and figure 1.5B). Despite its chemical and steric similarity with 4-oxo-folates 
(FOL, DHF, THF; figure 1.7), MTX binds in the active site with its pteridine moiety 
flipped 180° around the C6-C9 bond, relative to folate (figure 1.6). The main cause for 
this flip is probably the presence of the 4-amino group instead of a 4-oxo group. 
Consequently, active-site residues form different contacts with the two molecules, and 
binding of the inhibitor MTX is 2000-fold stronger than binding of the substrate DHF.  
Table 1.1 lists the residues that directly interact with DHF and/or MTX in the 
hDHFR ternary complex. The hydrogen bonding network involving structural water, the 
conserved active site residues Thr136, Glu30, Trp24 and the pteridine moiety of the 
bound folate is maintained, but in the case of MTX it involves the N1 and N8 nitrogen 
and the 2-amino group [22]. The 4-amino group of MTX interacts with residues Ile7, 
Val115 and Tyr121 and with NADPH [22]. The backbone carbonyl groups of both 
residue 7 and 115 are within H-bonding distance with the 4-amino group of MTX [44]. 
Moreover, the side chains of these two residues are likely to form hydrophobic 
interactions with the inhibitor’s pteridine moiety [44]. Residue Phe34 is also within the 
van der Waals distance with the pteridine moiety.[45] 
As in the case of folate, the p-ABA moiety of MTX forms van der Waals and 
hydrophobic interactions with the side chains of Phe31, Phe34, Ile60, Pro61 and Leu67 
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[22]. The carbonyl oxygen of p-ABA also forms a H-bond with the amide nitrogen of the 
Asn64 side chain [22]. 
The α-carboxylate portion of the glutamate moiety makes close contacts with the 
side chains of Arg70 (charge interaction) and Gln35. When the inhibitor does not occupy 
the active site, a subdomain shift brings Arg70 into contact with Gln35 [46]. 
Section 1.2.1.1 - Mechanism of resistance to MTX 
Some type of neoplastic diseases are intrinsically resistant to MTX whereas those 
that are responsive can develop resistance following repeated treatments (acquired 
resistance) [42]. MTX was brought into clinical use and became an established 
component of many clinical regimens right after the demonstration of its effectiveness in 
the late 1940s [33, 47], when its mechanism of action was not clearly understood. 
Between the end of the 1970s and the beginning of the 1990s, a better understanding of 
metabolism, transport and kinetics of binding of MTX to DHFR helped to elucidate the 
basis of MTX resistance. Different mechanisms of acquired resistance that impair 
efficiency of MTX-treatment have been described [5, 41, 42]. Amplification of the dhfr 
gene [48] or DHFR over-expression [49] were frequently observed. Moreover, 
mammalian DHFR expression is regulated by binding of its own mRNA at the active site 
[50]. In fact, hDHFR binds specifically to its own mRNA and this interaction represents a 
mechanism of inhibition of hDHFR mRNA translation [50]. Binding of MTX dislodges 
the DHFR mRNA, rendering it available for translation and therefore increasing protein 
expression. The higher the level of DHFR, the higher is the level of free-drug necessary 
to suppress THF regeneration. The free drug level is a critical parameter in the 
interactions between MTX and both hDHFR and folylpolyglutamate synthetase (FPGS; 
see section 1.0 for a detailed description of the carrier proteins and enzymes involved in 
folate metabolism). Transport mechanisms regulate the influx and efflux of drugs across 
the cell membrane, and the net effect of these processes determines the level of free MTX 
achieved intracellularly. Alteration in the expression or mutations of the reduced folate 
carrier protein (RFC) [51] and of FPGS [52] determine reduction of cellular uptake or 
allow more rapid efflux of MTX [41], respectively. MTX polyglutamates accumulate at 
different rates in a variety of tumor cells and ultimately become the predominant species 
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and the form of antifolate bound to hDHFR, and this is an important determinant of the 
pharmacologic activity of this drug. Impaired polyglutamation can therefore be a 
determinant cause of resistance together with the other possible resistance mechanisms. 
The above-mentioned MTX resistance mechanisms have all been observed either 
in tumours isolated from patients that relapsed during or following MTX-treatment, and  
ex vivo (by exposing cells isolated from patients to MTX in vitro) [48, 53-55]. An 
additional resistance mechanism is the occurrence of mutations in the dhfr gene, resulting 
in expression of hDHFR variants with reduced affinity for MTX. This mechanism of 
resistance was first observed in ex vivo studies, but it has never been identified as a cause 
of resistance in tumours isolated from patients who relapsed following MTX treatment. 
Even if it has been long proposed that mutations that confer resistance to MTX could 
occur in tumural cell of patients receiving a MTX-based therapy, and therefore 
contributing to their clinical relapse, a study performed by Spencer et al. described why 
this is unlikely to happen [56]. Briefly, the authors demonstrated that different mutations 
that occurred spontaneously and conferred MTX-resistance in ex vivo experiments, 
conferred only modest protection to MTX when transduced into cells using a retroviral 
vector. Moreover, accumulation of mutations that increase total MTX resistance seems 
unlikely because other mechanisms of resistance, as discussed above, prevail. Because it 
does not occur clinically, hDHFR MTX-resistant mutants represent a promising tool for 
gene theraphy, as it will be discussed in paragraph 1.2.1.3. Moreover, a second possible 
application would involve the use of these hDHFR MTX-resistant variants as selection 
markers for gene transfer into eukaryotic cells [57, 58].   
Section 1.2.1.2 - Mutations of hDHFR that confer resistance to MTX  
MTX-resistant mutants of DHFR from mammalian sources have been identified 
either in vivo, ex vivo (by exposing mammalian cells to MTX in vitro) or in vitro (created 
by mutagenesis).  
The MTX-resistant DHFR G15W was the only variant isolated in vivo, from a 
MTX-resistant subline of murine leukemic cells implanted in mice. Subsequent in vitro 
characterization of both the mouse and the human G15W variants, demonstrated that 
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although effectively resistant (200-fold increase in KiMTX for mouse DHFR), the mutant 
was too unstable to be the primary cause of the observed resistance [59].  
The first ex vivo studies reported in literature aimed to better understand the 
causes of emergence of MTX resistance. Mutation L22R [60] and F31W [61] were 
identified from MTX-resistant mouse cells, F31S from both hamster [62] and human [63] 
cells and F31W from both hamster [62] and murine [61] cells. In parallel, in vitro 
mutagenesis studies on E. coli, mouse and human DHFRs allowed characterization of the 
above-mentioned variants and identification of further mutations that confer resistance to 
MTX. All mutations characterized showed decreased affinity for MTX but also loss of 
catalytic activity, generally due to reduced DHF affinity. This result is readily 
rationalized by the fact that MTX and DHF make similar contacts with the enzyme, as 
illustrated in table 1.1 and figure 1.5.  
Mutations of hDHFR that confer resistance to MTX and their kinetics and 
inhibition parameters are listed in table 1.2. Leu22 is a highly-conserved active site 
residue that establishes van der Waals contacts with the pterin ring of bound MTX and 
NADPH [35]. Variants substituted with Phe, Arg, Trp or Tyr at position 22 are all MTX-
resistant and all exhibit a greater decrease in affinity for MTX than for DHF (table 1.2). 
Mutant L22F is the least resistant, presenting a moderate resistance and maintaining 
catalytic efficiency in the range of the native enzyme [43]. Decreased affinity for these 
mutants was associated with increased koff, and this may be due both to a decreased 
affinity between MTX and the active site or/and to an increased diffusion of MTX from 
the active site. When the crystal structures of hHDFR mutants L22R [43] and L22Y [43] 
in the ternary complexes with NADPH and MTX were compared with the wild-type 
hDHFR⋅NADPH⋅MTX ternary complex structure [64], a rational common explanation 
was difficult to postulate. In fact, while Arg22 appeared to have lost all close contacts 
with MTX by adopting a low probability conformation, Tyr22 showed the same contacts 
with MTX as the native Leu residue. Therefore, while in the case of L22R a loss of 
binding energy could partly explain the loss of affinity for MTX, such explanation was 
not valid in the case of the L22Y variant [43].  
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Phe31 and Phe34 belong to α-helix B and they both interact by van der Waals 
interactions with the pteridine extremity and the p-ABA moiety of MTX and DHF [22]. 
Replacements of residue Phe31 with the small amino acids Ala, Gly and Ser gave rise to 
moderately MTX-resistant mutants (70 to100-fold increase in KiMTX), with little loss of 
catalytic activity and DHF binding comparable to the native enzyme (table 1.2) [65]. The 
authors proposed that decreased MTX binding was due to the loss of interaction between 
the side chain of residue 31 and bound the MTX. Moreover, the absence of isomerisation 
of the initial complex, which increases the MTX binding of about 60-fold in the native 
enzyme, was proposed as further potential cause for the increase in KiMTX and for a little 
variation of KMDHF. The authors proposed that isomerisation of the 
enzyme·MTX·NADPH complex could depend on the motion of residue 31 [65], which 
occupies two alternative conformations in one crystal structure of folate complexed with 
hDHFR [18]. When a small residue replaces the bulky Phe, this conformational change 
does not occur and further stabilization of the complex cannot take place. Mutations at 
position 31 with the more bulky and hydrophobic amino acids Leu, Val and Thr did not 
significantly affect either catalysis or inhibitor binding [65]. Finally, mutation F31R 
conferred the highest degree of MTX-resistance at this position, again with a small effect 
on DHF binding, but with a 10-fold decrease in reactivity [57].  
Residue Phe34 is strictly conserved in DHFRs from all species. Nakano et al. [45] 
mutated residue 34 to Ala, Ile, Ser, Thr and Val and observed an important increase of 
both the ternary KDMTX and KDDHF. Mutation at residue 34 mainly increased the KDMTX by 
decreasing kon and largely increasing koff. In the case of F34T the effect on KDDHF was 
even more significant than the effect on KDMTX. The effect on reactivity was minimal in 
all cases. However, the effect of the described mutations on DHF binding indicates that 
position 34 in human DHFRs is likely essential for substrate binding, and therefore less 
tolerant to mutations. 
The backbone carbonyl of Ile7 is within H-bonding distance of the 4-amino group 
of the bound MTX and its side chain is likely to form hydrophobic interactions with the 
pteridine ring of the inhibitor [22]. Since the H-bonding interaction is not observed in the 
binary complex structure with bound FOL, mutations that disrupt this bond could 
potentially reduce the affinity to MTX while maintaining a native-like binding to the 
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substrate. However, the resolution of the structure of the binary wild-type hDHFR·5-
deazafolate complex indicates that it is possible that the N8 of DHF is protonated, 
contrary to folate, and that it can form an H-bond with the backbone carbonyl of Ile7. If 
this hypothesis is valid, mutation at residue 7 could also significantly affect the DHF 
binding. The only mutation described for hDHFR at this position is I7F. This mutation 
yielded a very unstable enzyme with a 7000-fold increase in KiMTX and a 370-fold drop in 
the DHF binding, suggesting that this highly conserved residue plays a role in both 
substrate and inhibitor recognition [57].  The Val115 backbone carbonyl also forms an H-
bond with bound MTX [22], and this interaction was never reported with either FOL [28] 
or 5-deazafolate [18].  Thillet et al. created mutant V115P of murine DHFR to disrupt the 
H-bonding between V115 and MTX. The mutation gave rise to a very unstable enzyme 
with no significant decrease in the MTX binding.[44] 
Arg70 is a highly conserved residue that forms a salt bridge with the α-
carboxylate portion of the glutamate of both DHF and MTX. Mutation R70K generated a 
stable enzyme with an increase of 4 orders of magnitude of the binary KDMTX (with 
respect to WT KiMTX) [46], and a 100-fold decrease in catalytic efficiency, due to a 
combined effect on both kcat and KMDHF. The authors proposed that the observed effect 
was due to the loss of protonation of Lys70. In fact, its pKa was lowered due to the 
hydrophobic environment in which the amino acid was buried. This result suggests that 
the loss of the salt-bridge with the glutamate moiety of MTX has an effect on both the 
ligand and the inhibitor binding. However, it is interesting to observe that the glutamate 
moiety does not appear to be essential to have inhibition. In fact, the antifolate 
trimetrexate (TMTX, figure 1.7), which does not possess the glutamate tail, also binds to 
hDHFR with a strong affinity (Ki = 13 pM) [35]. 
Finally, highly MTX-resistant hDHFRs were obtained by combining the L22 and 
F31 point mutants, which individually conferred a moderate MTX-resistance [66]. All  
double mutants tested had a higher KiMTX  (from 800 to 44000-fold) and only a slightly 
reduced (~5-fold) KMDHF than the native enzyme [66]. Both double mutants L22F-F31G 
and L22F-F31S showed a synergistic effect on the MTX binding [66]. 
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1.2.1.3 - MTX cytotoxictiy and gene therapy 
The therapeutic utility of MTX is impaired not only by the emergence of 
resistance but also by its indiscriminate cytotoxicity towards normal proliferative tissues, 
such as the gastrointestinal tract and the bone marrow (myelosuppression). Despite its 
toxicity, the safety and cost-effectiveness of MTX guarantees that it will continue to be 
administered in cancer therapy world-wide for the foreseeable future [5]. 
Toxicity can be partially managed clinically by modification of dosage and 
scheduling [5]. However, a more effective and durable approach could be to render 
normal tissues MTX-resistant by introducing a drug-resistant DHFR gene [57, 58]. The 
principle of protection of cells by means of a transgene is also known under the name of 
gene therapy. To overcome MTX-induced myelosuppression, this would involve 
transplantation of bone marrow with haematopoietic stem cell (HSCs; progenitor cells) 
previously transduced with retro-viruses introducing a resistant DHFR variant [67].  
MTX-resistant mammalian DHFRs are potential candidates for gene therapy and 
in fact, they have already been tested for MTX-protection both in murine and human cells 
lines [68-72]. Despite the fact that different problems (e.g. low efficiency of gene 
transfer, low long term expression, engraftment failure of ex-vivo manipulated cells, 
silencing of the transgene) have to be addressed before this approach becomes effective 
in clinical trials, the potential of this application remain undoubted [67]. 
Section 1.2.2 - Other antifolates  
MTX is the principal antifolate in use, but resistance and toxicity are current 
important limitations of a treatment with this drug [5, 41]. Attempts to improve the 
effectiveness and to overcome the side-effects related to the MTX treatment have 
promoted a search for alternative antifolates for the last 60 years, highlighting the 
importance of this area of investigation [73-76]. This research has led to the synthesis of 
inhibitors of different folate-requiring enzymes, inhibitors with multiple intracellular 
targets and inhibitors with different chemical and pharmacological features [74]. 
Pemetrexed (LY231514; figure 1.7), for example, inhibits four different folate-depending 
enzymes [77, 78] while trimetrexate (figure 1.7), being lipophilic and lacking the 
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glutamate tail portion, can circumvent the resistance associated with mutations of FPGS 
and with mutations of the folate transporters RFC and FBP [5].  
This section will focus on antifolates, different from MTX, which will be 
discussed in this thesis. The structures of all the molecules discussed are illustrated in 
figure 1.7. 
Trimethoprim (TMP; figure 1.7), a 2,4-diamino-pyrimidine ring connected with a 
trimethoxybenzyl moiety, is clinically used as an antibacterial drug [11]. TMP behaves as 
a classical competitive inhibitor of both bacterial and human DHFR [13]. However, it 
binds very tightly to DHFR from bacterial sources (Ki for ecDHFR = 80 pM) [13], but 
weakly to hDHFR (KD ternary complex = 0.5 μM; Ki = 0.96 ± 0.3 μM) [13], which is the 
basis for its bacterial selectivity. Therefore, inhibition of hHDFR by TMP is 280000-fold 
weaker than the binding of MTX.  
Trimetrexate (TMTX; figure 1.7) is a potent inhibitor of hDHFR (Ki = 13 pM) 
[35]. TMTX has structural and pharmacological properties different from MTX. First, it 
is lipophilic, and thus enters cells via passive or facilitated diffusion, without any need for 
folate transporter such as RFC and FBP. Then, it does not possess a glutamate tail and 
therefore it is not a substrate for FPGS. Unfortunately, this very promising antifolate 
failed phase II clinical trials for the treatment of different types of cancers, because it did 
not confer any real advantage with respect to the established treatments [79, 80]. From a 
structural point of view, TMTX remains interesting because, despite missing the 
glutamate tail, it binds very tightly to hDHFR.  
Pemetrexed (PMTX or LY231514; figure 1.7) [77] is a multi-target antifolate 
which was approved by the FDA in 2004 and it is used for the treatment of lung cancer 
and of some other types of solid cancers (bladder, breast, gastric and pancreatic cancer) 
[78]. Its main target is TS (Ki = 1.3 nM), but it also inhibits DHFR (Ki = 7.2 nM), 
GARFT (Ki = 65 nM) and AICARFT (Ki = 265 nM) [81]. Targeting multiple enzymes 
involved in purine and thymidylate biosynthesis offers a lower risk of resistance 
development and a more limited toxicity profile than other approaches [5]. PMTX 
contains a 6-5 ring-fused pyrrolo[2,3-d]pyrimidine system. Using molecular modeling, 
Gangjee et al. [73] suggested that PMTX binds to DHFR in the same orientation of FOL. 
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This hypothesis is supported by the observation that 5-deazafolate (figure 1.7)[18], 
which is a 4-oxo pteridine system structurally similar to both FOL and PMTX, binds in 
the same orientation as FOL. The only difference with folate is the replacement of the 
pteridine ring’s N5 with a carbon, which leads to a decrease of the polarity of this 
portion.  
 
Section 1.3 – Drug discovery and structure-activity 
relationship analysis  
To effectively prevent substrate binding and turnover efficient enzyme inhibitors 
must bind their target with both high affinity and high selectivity. Drug design consists in 
the tailored-synthesis of potential inhibitors based on detailed structural and functional 
information on the biological target of interest. Dorzolamide, an inhibitor of carbonic 
anhydrase, was approved in 1995 and it is one of the first examples of a structure-based 
drug design leading to an approved drug [82]. Drug discovery by high-throughput 
compound synthesis and screening is very expensive [76, 83, 84]. Therefore, to reduce 
costs and to increase efficiency, complementary approaches such structure-based 
computer assisted techniques (homology modeling [85], docking [86] and molecular 
dynamics simulations [87]) have been developed. Homology modeling, for example, 
allows building model structures for proteins by extrapolation of structural data from 
related proteins with homologous or similar sequences. Docking procedures allow fast 
screening of large compound libraries by evaluating the binding affinity to the target in 
silico. Molecular dynamics simulations, instead, can be used to model conformational 
changes upon binding. All these methods rely on structure-function information, and this 
is why structure-activity relationship (SAR) study is crucial for efficient drug discovery. 
Despite the large amount of information about drug-target interactions and the 
continuously evolving informatics tools to support this approach, the design of new 
enzyme inhibitors with a high level of confidence is still a challenge. This is mainly due 
to the complexity of active sites, where small details can make a difference. However, the 
more we know about the ligand-binding cavity of a target enzyme, the further we can 
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improve structure-based approaches that currently drive the drug discovery process to 
identify new specific binders [88-91].  
  
Section 1.4 – Presentation of the research project 
Our principal goal is to better understand the molecular determinants of enzyme-
ligand binding. In fact, notwithstanding the continuous increase in the number of ligand-
bound enzyme structures being resolved, crystal structures provide limited information 
relative to the binding process. Even when high-resolution structures of a drug-bound 
target are available, it is challenging to predict effects of mutations on the binding, just as 
it is difficult to predict how the modification of the drug will alter binding. We generally 
possess limited information relative to the contribution of specific contacts to the overall 
binding efficiency and selectivity. Faced with an enormous number of potential drug and 
target modifications, we must continue to develop approaches to efficiently screen 
through potential interactions in order to focus on the most interesting ones.  
Mutants with altered drug-binding properties represent a rich source of 
information about binding. We specifically focused on drug-resistance in the enzyme 
hDHFR, as a system to investigate the relation between structural variations of the target 
protein (using mutants) and/or of the drug (using different compounds), and their effect 
on binding. We propose to study the role of individual and combinatorial mutations of 
hDHFR on substrate binding and on antifolate sensitivity using directed evolution 
combined with structural and kinetic analysis.  
Drug-resistant mutants of hDHFR from different species were previously 
characterized in order to elucidate the catalytic mechanism [19] and the role of some 
active site residues in structure maintenance [46] and in binding [65, 66, 92] (see also 
section 1.3.1.2). However, data available is limited and does not explore exhaustively the 
binding-site to systematically study the hDHFR structure-function relationship. We will 
consider different mutations at each targeted position (by saturation mutagenesis) and 
simultaneous mutations at different sites (by combinatorial mutagenesis). Binding 
properties are related to the specific environment and are not necessarily the sum of 
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single properties. In fact, upon simultaneous mutation, residues may behave either in an 
independent or in an interdependent fashion toward the protein function [93]. Moreover, 
the combination of mutations can yield additive or partially additive effects, 
multiplicative effects (synergy) or antagonist effects on the enzyme activity [66, 94, 95]. 
The elucidation of these combinatorial effects and the deconvolution of the single 
contributions to the total effect will give us information about the binding. The questions 
we want to answer are the following. How do mutations, individual and combinatorial, 
affect the energy of binding? Which residues are important for binding of all compounds 
and which ones are responsible for ligand discrimination? How important is a  
hydrophobic contact for the overall binding? How significant are distal effect on binding? 
Human DHFR has been chosen due to its clinical relevance and to the fact that it 
is an ideal model system to verify the advantages of the proposed strategy. The findings 
of this study will increase our understanding of enzyme-inhibitor interactions and will 
provide a useful tool for the discovery of new and more efficient folate-analog inhibitors 
of hDHFR. Moreover, hDHFRs with an elevated resistance phenotype are interesting 
candidates for protection of healthy cells from the toxic side effects of MTX treatment 
using gene therapy (see section 1.2.1.3). To this aim, PhD student Jordan Volpato has 
devised a strategy for evaluating the protection efficiency of MTX-resistant hDHFR 
mutants in mammalian cells; this topic will not be covered in this M.Sc. thesis.  
 
The first specific goal described in this M.Sc. thesis was to develop an efficient 
screening strategy to identify active and antifolate-resistant mutants of hDHFR from 
large libraries of mutants. Identification of the variants of interest from libraries of 
mutants represents the crucial step for success of the directed evolution approach and it is 
an obligatory step to identify relevant candidates for structure-activity relationship 
analysis.  
The second specific goal was to participate in the development of a combined 
structural and kinetic strategy to analyse in detail the effect of mutations on binding. 
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Section 1.5 – Presentation of the experimental approach 
1.5.1 - Directed evolution 
Directed evolution is an efficient way to engineer the properties of proteins and to 
identify novel enzymes with tailor-made properties [96]. The approach mimics the 
principles of Darwinian evolution, but on a ‘laboratory’ scale-time, and it consists of two 
main steps: generation of genetic diversity (library creation) and selection/screening for 
the desired property (specificity, activity, catalytic efficiency, sensitivity to a drug etc.). 
 Creation of up to 1010 protein variants at the DNA level is presently an easy task, 
due to the advances in the recombinant protein engineering and the power of PCR 
techniques. Genetic diversity can be introduced by random mutagenesis (error prone-
PCR) [97], or by recombination (DNA shuffling) [98]. These techniques do not require 
an in-depth understanding of structure/function relationships. However, in the cases 
where functional or structural information exists, it can be advantageous to apply a semi-
random approach like saturation mutagenesis at specific residues [99, 100]. In this 
approach, directed evolution and rational design are combined in order to concentrate  
mutations where they offer a higher probability to be effective [100]. Variation and 
combination of these mutagenesis techniques have been extensively described in 
literature [100-103]. 
Once DNA libraries encoding the enzyme variants have been created, the hard 
task is to identify the variant(s) presenting the desired new property among all the 
possibilities available. This means that the likelihood of obtaining a variant of interest is 
limited by the effectiveness and the power of the selection/screening method available to 
detect it. When the enzymatic property of interest is essential for cell survival, it is 
possible to establish a selection strategy based on this feature [104]. Selection for survival 
is an ideal choice when it is applicable, its limit of detection being only the 
transformation efficiency for the type of cell utilized in the study (∼108/μg DNA, 
maximum ∼1010 for certain E. coli strains). Alternatively, screening methods could be 
applied. While different high-throughput screening (HTS) methods which can detect up 
to 1015 variants are available to detect binding interactions (two-hybrid systems [105], 
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phage-display [106], ribosome display [107], mRNA display [108], flow cytometry 
[109]), HTS for enzymatic activity is often harder to perform. The most commonly used 
screening methods are based on the assay of isolated bacterial cells on agar or in 
microtiter plates for the detection of coloured or fluorescent molecules, which are 
produced in a chemical reaction by means of the activity of interest, the major limit being 
the availability of robotic platforms to maximize screening capacity. 
1.5.1.1 – Mutagenesis of hDHFR 
First, active-site residues to be mutated were identified on the basis of 
crystallographic and/or functional data available for hDHFR. Since we are interested in 
binding at the folate–binding site, target amino acids were all chosen within or close to 
that area, were they were more likely to be effective [110]. Target residues were 
identified before my arrival in the laboratory by PhD student Jordan Volpato and they 
cover all the folate-binding site (figure 1.8). Among these, five residues have been the 
main target of the investigation presented in this thesis: Ile7, Gly15, Trp24, Arg70 and 
Val115 (figure 1.8, in yellow). Each of the 5 targeted residues was randomized by 
saturation mutagenesis using NNS codon degeneracy (N: 
adenine/cytosine/guanine/thymine; S: cytosine/guanine). This means that at each 
position, all 20 amino acids were allowed. 
1.5.1.2 - Screening for the properties of interest: activity and antifolate resistance 
Previously, PhD student Jordan Volpato developed an efficient bacterial 
complementation approach to select MTX-resistant clones (described in chapter 2). 
Bacterial selection has the advantage of being very high-throughput, but unfortunately 
bacterial survival under selective conditions is not a direct read-out of catalytic activity 
and selected variants are not necessarily amenable to detailed characterization (where 
‘amenable to’ refers to expression level, stability, solubility and/or activity) [111].  Since 
the subsequent steps of characterization are laborious and require the use of expensive 
compounds (NADPH and MTX), an improvement of the screening step was required. 
Therefore, a further step of screening using a plate reader-based activity assay in presence 
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of high concentrations of inhibitor was developed to identify only the best hits from 
bacterial selection, as it is described in chapter 3.  
Moreover, in order to investigate discrimination in ligand binding, the scope of 
the project was extended by developing a screening strategy for further phenotypes of 
interest: activity (efficient binding of DHF upon mutation) and resistance/sensitivity to 
other antifolates (TMP and PMTX).  
A protocol to quantify activity (kcat) and MTX resistance (IC50MTX) directly from 
cell lysates in microtiter plates was also developed.  
1.5.2 – Structure-function relationship analysis 
1.5.2.1 – Kinetic characterization of the mutants: determination of kinetic inhibition 
constants 
Positive hits from second-tier screening were over-expressed and purified in order 
to determine more precisely the kinetic and inhibition parameters in vitro. The kinetic 
parameters KM and kcat describe productive binding of the mutants for the substrate DHF 
and the reaction rate of reduction of DHF to THF, respectively. The inhibition constant Ki 
describes productive binding of a competitive inhibitor to the mutants’ active-sites. The 
value obtained for these parameters were correlated to the different mutations for 
structure-activity relationship analysis. 
We have also begun SAR with MTX by investigating the binding of its 
constituent fragments: DAP (2,4-diamino-6-(hydroxymethyl)pteridine), DAMPA (4-[N-
(2,4-diamino-6-pteridinylmethyl)-N-methylamino]benzoic acid) and p-ABA-Glu (para-
aminobenzoic acid-L-glutamate) to relevant MTX-resistant variants identified in our 
laboratory (figure 1.7; chapter 4). 
1.5.2.2 – Structural characterization of the mutants by computer-based molecular 
modeling 
As it is impossible to envisage resolving the structure of all the resistant variants 
identified, computer-based molecular modeling approaches were considered as tools for 
structural characterization.  
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First, energy minimization was used to compare the predicted structure of one 
novel identified MTX-resistant mutant to the crystal structure of the native enzyme 
complexed with MTX (chapter 2).  
Then, docking was evaluated as a tool to mimic DHF and inhibitor binding in the 
active-site pocket of the native enzyme. Advantages and limits of this technique for SAR 
analysis will be discussed in chapter 5.  
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Table 1.1. Active-site interactions between hDHFR and folate or methotrexate 
 
 Folate (1DHF.PDB)[28] Methotrexate (1U72.PDB)[22] 
Dihydrofolate or 
methotrexate 
component 
hDHFR 
residue Type of interaction 
hDHFR 
residue Type of interaction 
I7 
Backbone carbonyl: 
hypothesized H-bond with N8 
DHF (not observed with FOL 
in 1DHF.PDB structure). 
Side-chain: hydrophobic 
I7 
 V115 
Backbone carbonyl: H-bond 
with 4-amino group. 
Side-chain: hydrophobic 
 T121 Side chain: H-bond with  4-amino group 
 
 
L22 
F31 F31 
F34 
Van der Waals/hydrophobic 
F34 
Van der Waals/hydrophobic 
W24 W24 
E30 E30 
Pteridine ring 
T136 
H-bonding network involving 
structural waters, N3, O4 and 
2-amino group T136 
H-bonding network involving 
structural water 216, N1, N8 
and 2-amino group 
F31 F31 
F34 F34 
I60 I60 
P61 P61 
L67 
Van der Waals/hydrophobic 
L67 
Van der Waals/hydrophobic 
N10-methyl-p-ABA 
N64 H-bond to p-ABA carbonyl oxygen N64 
Side chain: H-bond to p-ABA 
carbonyl oxygen 
R28 
Carbonyl backbone:  
H-bonding network between 
H2O410 and γ-COOH FOL 
(rarely observed) 
H2O198 
H-bonding network between 
carbonyl backbone N64, 
backbone NH, K68, α-COOH 
MTX 
Q35 In proximity to both 
α− and γ−COOH FOL Q35 
In proximity to both 
α− and γ−COOH MTX 
L-glutamate 
R70 Salt-bridge with α−COOH FOL R70 
Salt-bridge with α−COOH 
MTX 
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Table 1.2. Mutations providing MTX-resistance in hDHFR 
 
 
 
a Ternary KDDHF values. The KMDHF could not been determined cause of substrate inhibition. Since 
the rate of the chemical reaction is much slower than the rate of subsequent dissociation of THF, 
Nakano et al. used  ternary KDDHF values as an approximation of KMDHF [45]. 
b Derived from plots of rate versus DHF concentration by least-square fit to the equation for 
substrate inhibition by Nakano et al.[45]. 
c Calculated from kcat/KM and KMDHF, using the approximation described in a and b[45]. 
d Ternary KDDHF values [45]. 
e KiMTX calculated from data in figure 5a of Thompson and Freisheim (1991) [46]. 
 
 
 
 
hDHFR variant KMDHF 
(µM) 
Ratio   
KM mut/ 
KM WT 
kcat 
(s-1) 
kcat/KM 
(μM-1s-1)  
KiMTX 
 (nM) 
Ratio   
Ki mut/ 
Ki WT 
Native  ≤0.075 1 10 92 0.034 1 
Position 7 I7F [57]  20.5  270 5 0.25 24.6 7200 
Position 15 G15W [59]  6.2  80 3.2 0.5 2.1 600 
L22F [43] 3.9  50 23.8 6.1 0.5 150 
L22R [43] 1.6  20 0.04
5 
0.03 4.6 1300 
L22W [43] 0.4  5 4.2 10 4.3 1300 
Position 22 
 
L22Y [43] 0.5  5 6.1 12 11 3200 
F31A [65]  0.5  5 13.9 30 0.27 80 
F31G [65]  0.4  5 11.3 26 0.35 100 
F31S [65] 0.4  5 7.0 16 0.24 70 
Position 31 
F31R [57]  0.6  10 0.9 1.5 7.2 2100 
F34A [45] 36 a  480 8.4 c 0.2 b 34d 10000 
F34I [45] 24 a   320 13.7 c 0.6 b 13d 3800 
F34S [45] 350 a  4600 6.0 c 0.02 b 210d 60000 
F34T [45] 300a  4000 3.3 c 0.1 b 9.6d 2800 
Position 34 
 
F34V [45] 63a  800 30.7 c 0.5 b 10 3000 
Position 70 R70K [46]  0.5  5 1.75 3.7 0.46e 13 
L22F/F31G [66]   0.4  5 1.3 3.3 29 850 
L22F/F31S [66] 0.4  5 1.6 3.6 26 7600 
L22Y/F31G [66] 0.3  5 0.5 1.4 150 44000 
Double 
mutants 
 
L22Y/F31S [66] 0.3  5 1.3 3.8 42 12000 
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Figure 1.1. Folate–dependent metabolic reactions. The abbreviation are: DHFR, 
dihydrofolate reductase; TS, thymidylate synthase; GARFT, glycinamide ribonucleotide 
formyl transferase; AICARFT, aminoimidazole carboxamide formyl transferase; DHF, 
dihydrofolate; THF, tetrahydrofolate; 5-CH3-THF, 5-methyl tetrahydrofolate; 5,10-CH2-
THF, 5,10-methylene tetrahydrofolate; 5,10-CH-THF, 5,10-methenyl tetrahydrofolate; 5-
CHO-THF and 10-CHO-THF, 5-formyl- and 10 formyl tetrahydrofolate, respectively. 
Image was adapted from Figure 1 in Zhao et al. 2003 [41]. 
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Figure 1.1a: Synthesis of thymidylate (dTMP) from deoxyuridine monophosphate 
(dUMP). The enzymes dihydrofolate reductase (DHFR) and Serine hydroxymethyl 
transferase are necessary for the recycling of the 5,5-CH2-THF. In dTMP, all the methylic 
hydrogens (in red and blue) derive from 5,5-CH2-THF. Figure adapted from reference 
[2]. 
a 
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Figure 1.1b: Role of the folate cofactor 10-formyl tetrahydrofolate (10-CHO-THF) 
in the synthesis of the inosine nucleus. A) Conversion of tetrahydrofolate (THF) to 10-
formyl tetrahydrofolate (10-CHO-THF). B) Structure of inosine monophosphate (IMP), 
first intermediate to posses a complete purine nucleus. The carbons added by GARFT 
(glycinamide ribonucleotide formyl transferase) and AICARFT (aminoimidazole 
carboxamide formyl transferase), derived from formate and provided by 10-CHO-THF, 
are indicated in blue. Figure adapted from reference [2]. 
b 
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Figure 1.2. Reaction catalyzed by dihydrofolate reductase (DHFR). A) Reduction 
catalyzed by vertebrate DHFRs. B) Schematic representation of the hydride transfer in 
the transition state: optimal carbon-carbon bond distance and -C⋅⋅⋅H⋅⋅⋅C- bond angle are 
indicated. Image adapted from Benkovic et al. 1988 [15].  
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Figure 1.3. Sequence and structural comparison of human, murine and E. coli 
dihydrofolate reductases (DHFRs). A) Sequence comparison. Sequence differences 
from human DHFR are coloured in cyan for mouse DHFR and in red for E. coli DHFR. 
B) Comparison of the backbone of human (1U72.PDB; green) and E. coli (1RX3.PDB; 
magenta) and of human (1U72.PDB; green) and mouse (1U70.PDB; orange). Figure 
adapted from Cody et al. 2005 [22]. 
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Figure 1.4. Secondary structure of hDHFR. Eight-stranded twisted β-sheet (βA, 
residues 4-10; βB, 47-53; βC, 71-76; βD, 88-90; βE, 108-116; βF, 130-139; βG, which is 
interrupted by a tight turn is composed by βG1, 157-159 and βG2, 168-172; βH, 175-
185). Five α−helices (αB, 27-40; αC, 53-59; αΕ, 92−102 and αΕ’, 102-109; αF, 117-
127), a polyproline-like helix (Pro(II), residues 21-26) and eight tight turns (residues 11-
14, 18-21, 43-46, 61-64, 67-70, 83-86, 162-165, 172-175) connect the β-sheets among 
them. 
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Figure 1.5. Ligand binding at the active site of WT hDHFR. A) Bound folate (FOL; in 
green) from 1DHF.PDB. B) Bound methotrexate (MTX; in magenta) from 1U72.PDB. 
The active site is shown. Active-site residues that interact with the ligands are shown in 
sticks representation and coloured in orange, yellow or blue to indicate interaction or 
proximity to the ligand’s pteridine, p-ABA or glutamate moiety, respectively. The 4-
carbonyl and the 4-amino group of FOL (in A) and of MTX (in B) are circled to highlight 
the pteridine ring flip. 
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Figure 1.6. Binding of folate and methotrexate in the active site. Superimposition of 
1DHF.PDB (binary complex WT hDHFR⋅folate) and 1U72.PDB (ternary complex WT 
hDHFR⋅NADPH⋅MTX). FOL (in green; from 1DHF.PDB) and MTX (in magenta; from 
1U72.PDB) are visualized in the active site (from 1U72.PDB). The FOL 4-carbonyl 
group and the MTX amino group are indicated to show the pteridine ring flip between the 
two bound molecules.  
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Figure 1.7. Structural representation of the DHFR substrate dihydrofolate (DHF) 
and different antifolates relevant to this study. Atom numbering is indicated for both 
DHF and MTX. The substrate and the inhibitors PMTX and 5-deazafolate carry a 4-oxo 
functionality, while all the other inhibitor illustrated carry an amino group at position 4. 
MTX and its fragments are represented in the box. DAP (2,4-diamino-6-
(hydroxymethyl)pteridine), DAMPA (4-[N-(2,4-diamino-6-pteridinylmethyl)-N-
methylamino] benzoic acid) and p-ABA-Glu (para-aminobenzoic acid-L-glutamate).  
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Figure 1.8. Active-site residues of hDHFR targeted by mutagenesis. Bound folate 
(FOL; in green) from 1DHF.PDB and bound methotrexate (MTX; in magenta) from 
1U72.PDB are visualized in the active site (from 1U72.PDB). Active-site residues chosen 
as targets of this directed evolution study are shown in sticks and are coloured in yellow 
(principal targets discussed in this thesis) or orange. Residues Phe31, Phe34 and Gln35 
(in orange) are also discussed in this thesis, but they were mainly studied by Ph.D. 
student Jordan Volpato.  
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Chapter 2 (Article 1) – Increasing methotrexate 
resistance by combination of active-site mutations in 
human dihydrofolate reductase 
 
Section 2.0 – Preface 
Highly MTX-resistant mutants of hDHFR are potential candidates for protection 
of healthy haematopoietic stem cells from the cytotoxicity of MTX by means of gene 
therapy [67]. Mutations of active site residues of hDHFR can reduce affinity of the 
inhibitor, thereby conferring MTX-resistance, while maintaining sufficient substrate 
binding to allow catalysis [112]. Synergistic effects on MTX-resistance have been 
previously described by combining two active-site mutations that individually conferred 
moderate resistance to the drug [66]. Article 1 describes the use of a directed evolution 
approach in order to obtain highly MTX-resistant mutants for protection of a model 
mammalian cell system from the toxicity of this drug.  
Simultaneous mutagenesis to a variety of amino acids was performed at three 
specific active-site residues (Phe31, Phe34 and Gln35). Then, the development and 
application of an efficient selection strategy based on bacterial complementation allowed 
the identification of 10 highly MTX-resistant variants of hDHFR. While the residues 
targeted were all individually known to confer resistance to MTX upon mutation, 
characterization of the MTX inhibitory constant for the mutants identified showed that 
combinations of mutations can effectively lead to higher resistance, the most resistant 
mutant identified presenting three simultaneous mutations. This demonstrated the validity 
of the proposed approach for identification of mutants of interest. In silico energy 
minimization of the most MTX-resistant triple mutant and of the native enzyme was 
performed in order to postulate a structural explanation for the effects of mutation on 
inhibitor binding. Finally, mutants with the higher KiMTX were tested for their ability to 
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protect DHFR-knock-out Chinese hamster ovary cells from MTX-toxicity and showed 
100 to 400-fold higher degree of protection than the native enzyme. 
 My contribution to the article was limited to molecular modeling. PhD student 
Jordan Volpato was responsible of the totality of the experimental work, and together 
with Prof. Joelle Pelletier provided the design of the project and the edition of the article. 
Although my contribution to this paper was minor, molecular modeling associated to 
kinetic analysis offers a powerful tool for structure-activity relationship (SAR) studies, 
which ultimately is one of the major goals of the project. While crystal structure 
resolution is certainly the best approach to investigate structural consequences of 
mutations, it has proven challenging in the context of this project, such that molecular 
modeling has been deemed an essential alternative. Therefore, my contribution added 
value to the article by allowing to propose a reasonable structural explanation for the 
decreased binding, in absence of experimental structural evidence. This subject will be 
further discussed in chapter 5.  
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ABSTRACT 
Methotrexate-resistant forms of human dihydrofolate reductase have the potential 
to protect healthy cells from the toxicity of methotrexate (MTX), to improve prognosis 
during cancer therapy. It has been shown that synergistic MTX-resistance can be 
obtained by combining two active-site mutations that independently confer weak MTX-
resistance. In order to obtain more highly MTX-resistant human dihydrofolate reductase 
(hDHFR) variants for this application, we used a semi-rational approach to obtain 
combinatorial active-site mutants of hDHFR that are highly resistant towards MTX. We 
created a combinatorial mutant library encoding various amino acids at residues Phe31, 
Phe34 and Gln35. In vivo library selection was achieved in a bacterial system on media 
containing high concentrations of MTX. We characterized ten novel MTX-resistant 
mutants with different amino acid combinations at residues 31, 34 and 35. Kinetic and 
inhibition parameters of the purified mutants revealed that higher MTX-resistance 
roughly correlated with a greater number of mutations, the most highly-resistant mutants 
containing three active site mutations (KiMTX = 59 to 180 nM; wild-type KiMTX < 0.03 
nM). An inverse correlation was observed between resistance and catalytic efficiency, 
which decreased mostly as a result of increased KM toward the substrate dihydrofolate. 
We verified that the MTX-resistant hDHFRs can protect eukaryotic cells from MTX 
toxicity by transfecting the most resistant mutants into DHFR-knock-out CHO cells. The 
transfected variants conferred survival at MTX concentrations between 100-fold and 
>4000-fold higher than the wild-type enzyme, the most resistant triple mutant offering 
protection beyond the maximal concentration of MTX that could be included in the 
medium. These highly resistant variants of hDHFR offer potential for myeloprotection 
during administration of MTX in cancer treatment.  
 
Keywords 
Dihydrofolate reductase; mutagenesis; drug resistance; enzyme kinetics; in vivo selection. 
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INTRODUCTION 
Human DHFR (EC 1.5.1.3) is a ubiquitous cytosolic enzyme that catalyzes the 
reduction of 5,6-dihydrofolate (DHF) to 5,6,7,8-tetrahydrofolate (THF) in a nicotinamide 
adenine dinucleotide phosphate (reduced form) (NADPH)-dependent reaction. THF is an 
essential cofactor in several metabolic pathways, including purine and thymidylate 
biosynthesis. As a result of its importance in cellular proliferation, hDHFR has long been 
a key pharmacological target for the treatment of various types of cancer.1 Methotrexate 
is a folate analogue that acts as a slow, tight binding competitive inhibitor of hDHFR, 
thereby inhibiting cellular THF synthesis and cellular proliferation. MTX is widely used 
for the treatment of acute lymphoblastic leukemia, 2 osteosarcoma, 3 breast cancer,4 and 
head and neck cancer. 5  
Efficacy of MTX in cancer treatment is largely attributed to the high affinity of 
the drug for hDHFR (Ki = 3.4 pM).6 Crystal structures of the wild-type (WT) hDHFR 
complexed with MTX have shown that, despite its high structural similarity to folate, 
MTX and folate bind at the active site in a different orientation.7 Although the ρ-
aminobenzoic acid and glutamate (ρ-ABA-Glu) portions of both ligands bind at the active 
site in a similar orientation, the pteroyl moiety of MTX is flipped 180° around the C6-C9 
bond (figure 2.1(a)), such that its 4-amino group forms specific hydrogen bonds with the 
backbone carbonyls of residues Ile7 and Val115 (figure 2.1(b)), in contrast to bound 
folate, which does not form hydrogen bonds with these residues. The pteroyl moiety of 
MTX is also involved in hydrogen bonding with residue Trp24 via a conserved water 
molecule and with residue Glu30,8 while the side chain of residues Leu22 and Phe34 are 
within van der Waals distance of this portion of the inhibitor (figure 2.1(b)).9, 10 These 
interactions are also formed with the pteroyl moiety of folate, albeit with the opposite 
side of the pterin ring. The ρ-ABA moiety of MTX and DHF mainly interact via van der 
Waals interactions with residues Phe31 and Phe34 of α-helix 1 (residues 27-40), which 
also contains Gln35 that is proximal to the γ-glutamate moiety of the bound ligands. The 
glutamate moiety also forms a salt bridge with the guanidinium side chain of Arg70.  
Previous studies of hDHFR and murine DHFR have shown that certain mutations 
at residues Leu22, Phe31, Phe34, Gln35 and Arg70 (figure 2.1) can yield catalytically-
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active, MTX-resistant mutants.11-17 Identification of MTX-resistant hDHFR mutants has 
been performed either ex vivo in cultured cells exposed to MTX18-20 or by performing 
site-directed mutagenesis at the active site of hDHFR by rational design.9, 11-15, 21 These 
studies have mostly yielded point mutants that maintain good catalytic efficiency while 
displaying moderate MTX resistance (e.g. F31S, Ki = 0.240 nM; L22R : Ki = 4.6 nM).14, 
15 However, some point mutations confer high MTX resistance (e.g. F34S : ternary KDMTX 
= 210 nM), albeit with considerably reduced catalytic efficiency.10 These studies led to a 
better understanding of ligand binding at the enzyme active site and contributed to 
structure-based design of new antifolate inhibitors.22 
Identifying more highly MTX-resistant hDHFR mutants offers important 
applications in the medical field. Because MTX-resistant hDHFRs have not been 
observed in clinical studies of acquired MTX-resistance in cancer patients,23 MTX-
resistant hDHFRs have the potential to protect healthy haematopoietic stem cells from 
MTX toxicity during chemotherapy,24 thus protecting patients from immunosuppression. 
Gene therapy strategies have been used to transfer MTX-resistant hDHFRs into mouse 
and human bone marrow progenitor cells, efficiently ensuring stem cell survival upon 
exposure to MTX.25, 26 Resistant cells transplanted in the bone marrow of mice ensured 
myeloprotection during treatment with MTX.27, 28 For this application, ideal candidate 
hDHFR mutants should have a very high Ki for MTX (in the high nanomolar range), 
while maintaining the catalytic properties, including DHF binding , required to ensure 
cell survival.  
Highly MTX-resistant hDHFR genes with good catalytic efficiencies have been 
obtained by the combination of the moderately MTX-resistant point mutants at active-site 
residues 22 and 31,29 which generated synergistically resistant hDHFRs (e.g. L22Y-
F31G, Ki = 150 nM versus L22Y, Ki = 11 nM and F31G, Ki = 0.35 nM) that conferred 
high MTX resistance in human and mouse stem cell lines. While those results are 
promising, variants that are yet more highly resistant and/or more active would hold 
greater potential for clinical application, by increasing the difference in cellular survival 
between cells harboring MTX-resistant hDHFR and those with native hDHFR (target of 
MTX).    
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On the basis of these considerations, we have devised a strategy based on directed 
evolution for the identification of novel hDHFR combinatorial mutants that are highly 
active and resistant to MTX. Directed evolution of ligand binding in an enzyme generally 
requires structure-based knowledge to pinpoint residues in the vicinity of the active site. 
These residues are mutated in combination and the resulting combinatorial mutant 
libraries are screened for a desired property. Application of such methods has provided 
new structural insight into ligand binding,30,31 engineered new substrate specificity,32 and 
resulted in the development of efficient biomarkers.33,34 Using a semi-rational approach, 
we created a combinatorial library encoding mutations at residues Phe31, Phe34 and 
Gln35 of the hDHFR gene. These residues belong to α-helix 1 and are individually 
known to confer MTX resistance upon mutation.10,14,17 We performed in vivo library 
selection in a bacterial system propagated on media containing a high concentration of 
MTX. Characterization of selected variants yielded novel MTX-resistant hDHFR 
mutants, including a variety of combinatorial mutants that displayed an important 
decrease in MTX binding, comparable to the weakest-binding hDHFR mutant reported to 
date, albeit with a greater residual specific activity. As a result, we obtained very efficient 
protection of a relevant mammalian cell model, dhfr - CHO DUKX B11 cells.  
 
RESULTS 
Creation of the hDHFR mutant library  
 A combinatorial library encoding 567 different mutants was created by mutating 
amino acids Phe31, Phe34 and Gln35 to a selection of amino acids, in order to identify 
novel MTX-resistant hDHFR mutants (table 2.1). The number of possibilities encoded 
was restricted in view of future recombination with other mutant hDHFR libraries. The 
three positions chosen for mutation belong to α-helix 1 (residues 27-40), which contains 
the catalytic residue Glu30, a highly-conserved residue that protonates N5 of DHF prior 
to hydride transfer,8 as well as residues Phe31, Phe34, Gln35, that have been shown to be 
important for substrate and/or inhibitor binding.10,14,17 The selection of amino acids to be 
encoded at positions 31, 34 and 35 was based either on known mutations that individually 
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confer resistance to MTX or on the basis of in silico observations of hDHFR with bound 
MTX. We encoded the desired mutations at the three positions using a single degenerate 
oligonucleotide primer. As a result of codon degeneracy, other amino acids were encoded 
in addition to the amino acid variety of interest (table 2.1). Site-directed mutagenesis 
studies at residues 31 and 34 have shown that MTX-resistant mutants generally contain 
small polar or non-polar amino acids at these positions. Consequently, these types of 
residues were encoded in addition to the phenylalanine present at these positions in WT 
hDHFR. As noted in previous reports,7,35-37 visualization of bound MTX or folate in the 
native enzyme (figure 2.1) suggests that these substitutions can reduce the contact 
surface with bound ligand, therefore reducing affinity for MTX and/or DHF. For residue 
35, earlier studies of the murine DHFR gene have shown that the mutation Q35P can 
confer moderate resistance to MTX.17 The location of the Q35P mutation in the middle of 
α-helix 1 suggests a change in α-helix geometry. Consequently, we mutated Gln 35 to 
amino acids with low α-helical propensity,38 without encoding proline due to low stability 
of the Q35P point mutant.17  
 
Selection and identification of MTX-resistant mutants  
 The hDHFR mutant library was transformed in Escherichia coli SK037, a MTX-
sensitive strain. This strain is a knock-out for tolC, which encodes a protein essential to 
the function of a multi-drug-resistance (MDR) efflux pump.39 The quality of the library 
was assessed by sequencing 70 clones that grew on non-selective media (LA-100). 
Nucleotide representation for each of the degenerate codons used at residues 31, 34 and 
35 followed the expected statistical distribution, and no non-specific mutation was 
observed. The library was then selected on M9 minimal medium containing 1 mM MTX 
(ATM-1000). As negative controls for MTX-resistance, E. coli SK037 transformed with 
pQE32 or WT hDHFR-pQE32 were also plated on the selective medium. The survival 
rate of the library was 0.2%, whereas no bacterial growth was observed for the negative 
controls. E. coli SK037 transformed with hDHFR L22Y-pQE32, which encodes a MTX-
resistant point mutant of hDHFR, were plated on the selective ATM-1000 medium as a 
positive control. This yielded a 100% survival rate relative to non-selective medium, 
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demonstrating that the selection stringency was appropriate for identification of MTX-
resistant hDHFR mutants. Seventy colonies were picked following selection to identify 
the mutations at positions 31, 34 and 35. As shown in figure 2.2, ten different mutants 
were identified post-selection. The mutants are designated by the one-letter code of the 
amino acid occurring at positions 31, 34 and 35. The selection yielded 1 point mutant, 
five double mutants and four triple mutants. Mutant PFE was the most frequently selected 
combination (30%), followed by SFE (27%), RFE (20%) and PFH (11%). These variants, 
which are all double mutants, represent 88% of the selected clones and all contain the 
native Phe residue at codon 34. The last double mutant identified, GFN, also conserves 
the native Phe at position 34, but was identified only once (1%). The most frequently 
observed triple mutant is AVH, identified 5 times (7%), followed by RTR (1%), RTS 
(1%) and RAN (1%). Finally, a point mutant, PFQ (F31P) was identified once (1%). This 
point mutant had not yet been characterized in MTX-resistance studies. Retransformation 
and plating in the presence (ATM-1000) or absence (LA-100) of MTX gave rise to a 
similar number of colonies for all selected variants, confirming that the observed 
resistance is solely due to the MTX-resistant hDHFRs. 
Binding and kinetic characterization of MTX-resistant hDHFR mutants  
 For determination of kinetic and binding parameters, the retransformed MTX-
resistant hDHFR variants were purified in one step to 90-95% purity, with yields ranging 
between 1-30 mg/L of culture (data not shown). Solubility and relative expression level 
of all variants upon over-expression was verified by loading volume-equivalent amounts 
of total cell extracts, cell pellet and supernatant for resolution by SDS-PAGE. All His6-
hDHFR variants were approximately 50% soluble, as reported for the native recombinant 
hDHFR,40 ruling out solubility differences in explaining the observed variations in yield 
of purified variants. In addition, all mutants (soluble + insoluble) were expressed at 
similar levels. The mock-purified supernatant of E. coli SK037 transformed with the 
vector pQE32 served as a negative control in all kinetic and binding experiments.  
Michaelis constants for the substrate DHF (KMDHF) and reactivity (kcat) were 
determined for the ten selected mutants and for WT His6-hDHFR. KMDHF of WT His6-
hDHFR was determined to be <75 nM. At this concentration of DHF, the enzyme was 
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already saturated. It was not possible to obtain a more precise value due to the weak 
signal observed at such a low concentration of substrate. Previously reported KMDHF 
values for recombinant, native (non-His-tagged) WT hDHFR are in the range of 33 to 
120 nM,6,15,20 suggesting that the His6-tag has little effect on DHF affinity. KMDHF was 
increased at least ninefold to 57-fold for the selected mutants relative to WT His6-hDHFR 
as a result of the mutations introduced at positions 31, 34 and/or 35. This was not 
unexpected, as the residues chosen for mutagenesis are known to be involved in DHF 
binding. As shown in table 2.2, kcat values were reduced by at most a factor of 10, except 
for mutant RAN (20-fold decrease); mutants PFQ, GFN and SFE displayed kcat values 
similar to that of native enzyme. The lowest reactivities were generally displayed by 
mutants containing a F31R substitution, which is consistent with previous reports of this 
point mutant (kcat = 0.93 s-1).41 As a result of the kcat and KMDHFvariations, the catalytic 
efficiencies (kcat/KMDHF) for all selected mutants were reduced, ranging from a 30-fold 
decrease for point mutant PFQ to a 700-fold decrease for triple mutant RAN (table 2.2). 
 The inhibition constants for MTX (KiMTX; table 2.2) reveal that all selected 
mutants were resistant to MTX, the most highly resistant being the AVH triple mutant 
(KiMTX = 180 nM), with KiMTX almost 4 orders of magnitude greater than WT. The mutant 
with the lowest Ki is the point mutant PFQ (KiMTX = 1.7 nM), which was inhibited 50-fold 
less efficiently by MTX than the WT enzyme, while the other combinatorial double and 
triple mutants showed Ki increases of at least 2 orders of magnitude (table 2.2, figure 
2.3). Ternary binding constants for MTX were also determined, to verify that the 
observed loss of inhibition correlated with reduced binding. The ternary KDMTX values 
obtained were similar to the KiMTX values for all mutants (table 2.2), indicating a direct 
relation between binding and inhibition in all cases. The greatest difference between Ki 
and KD was for mutant RTR (eightfold). It was not possible to determine the KD values 
precisely for WT His6-hDHFR, PFQ and RAN mutants by this method, the fluorescence 
quenching detection limit being ~2 nM MTX in our system. Binary KDMTX values were 
also obtained in absence of NADPH for the MTX-resistant mutants (results not shown). 
In all cases, the value for the binary KDMTX was greater than the ternary KDMTX (fourfold to 
19-fold difference for tested mutants RTR, RTS, RFE and AVH). This is consistent with 
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bound NADPH promoting tighter binding of MTX to the selected hDHFR variants, as 
demonstrated for the native enzyme.6 
Protection of mammalian cells with mutant hDHFRs  
 We verified the efficacy of eukaryotic cell protection with four of the selected 
mutants (table 2.3). CHO DUKX B11 cells (dhfr-) were transfected with mutant RFE, 
SFE, RTS or AVH. These variants were chosen because they displayed the highest KiMTX 
values while maintaining catalytic efficiency comparable to MTX-resistant hDHFRs used 
in similar studies.42-44 WT hDHFR and the MTX-resistant point-mutant L22Y served as 
negative and positive controls, respectively. A mock experiment consisted in transfecting 
pcDNA 3.1 vector (null). Transfection efficiency was evaluated at approximately 50% 
for all constructs. Transfected cells were exposed to various concentrations of MTX for 
48 hrs in α-MEM medium containing no nucleotides, ensuring that cell survival was 
based solely on activity of the transfected hDHFRs. Figure 2.4 presents cell survival 
data; EC50MTX values are given in table 2.3. All mutants tested conferred MTX-resistance 
to CHO DUKX B11 cells. The point mutant L22Y (EC50MTX = 12 μM) provided a 220-
fold increase in EC50MTX relative to the WT hDHFR (EC50MTX = 0.054 μM). The double 
mutants RFE (EC50MTX = 31 μM) and SFE (EC50MTX = 32 μM) provided a 570-fold 
increase, while the triple mutant RTS (EC50MTX = 56 μM) provided a 1030-fold increase 
relative to WT. The EC50MTX for the triple mutant AVH (>4000-fold increase) could not 
be determined because dissolution of higher concentrations of MTX in the medium 
perturbed the pH. Mutant AVH allowed survival of 73% of the cell population at 200 µM 
MTX. Enzyme expression under these conditions was confirmed by Western blot 
analysis (data not shown). The null control showed no cell survival, confirming that 
survival was due solely to the presence of MTX-resistant hDHFRs, and that no secondary 
resistance mechanism had been acquired upon exposure to MTX. Cells expressing WT 
hDHFR were sensitive to low concentrations of MTX, ruling out gene amplification.  
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DISCUSSION 
Of 567 possibilities encoded in the hDHFR mutant library, ten MTX-resistant 
mutants were identified following selection on solid media containing 1 mM MTX. The 
chosen selection strategy yielded one novel single mutant and nine novel combinatorial 
MTX-resistant mutants, providing new insight into the role of residues at positions 31, 34 
and 35 in ligand binding and selectivity, while generating novel hDHFR mutants that 
efficiently protect CHO (dhfr-) eukaryotic cell line from MTX-cytotoxicity.  All of the 
resistant mutants displayed reduced catalytic efficiencies compared to WT His6-hDHFR 
(30 to 700-fold decrease), mainly as a result of decreased productive binding of DHF 
(tenfold to 60-fold KMDHF increase). The reduction in MTX affinity was much greater, 
with KiMTX increased 54 to 5800-fold. Thus, we identified a variety of patterns of 
mutations at active-site residues 31, 34 and/or 35 that greatly reduce the binding of MTX 
while maintaining sufficient affinity for DHF to provide the level of catalytic activity 
required for bacterial propagation. The various sequence patterns obtained are indicative 
of significant plasticity and robustness in these active-site residues: a low number of 
mutations were sufficient to induce a new phenotype (high MTX resistance resulting 
from plasticity) while the native function, THF synthesis, endured the effect of the 
mutations to an important degree as a result of robustness.45 
Consistent with previous reports of hDHFR point mutants of Phe31,14 we 
observed the bulky, positively-charged Arg and small residues, whether polar or non-
polar (Gly, Ala and Ser) at position 31 (table 2.4). The variety of amino acids identified 
at position 31 (five of the nine encoded) confirms that this position can tolerate a variety 
of side-chain volumes and functional groups. Arg31 was encoded in four of the resistant 
mutants, consistent with F31R being the most resistant Phe31 point mutant reported 
(KiMTX = 7.2 nM).41 In addition, we observed the structurally-constraining proline at 
position 31 (point mutant F31P, or PFQ). Never previously reported, this MTX-resistant 
point mutant exhibits resistance and catalytic efficiency intermediate between the 
previously-reported F31R and F31S point mutants.14,41  
Phe34 was the most strongly conserved native residue, consistent with previous 
studies qualifying the importance of Phe34 in binding either MTX or DHF at the active 
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site.10 Three of the four amino acids encoded were observed in the four triple mutants we 
identified (Ala, Thr or Val). Previously-characterized point mutants were not identified 
by our screening strategy, likely because the in vivo MTX-resistance trait that we selected 
for is complex, requiring low MTX binding combined with sufficiently high specific 
activity as well as good expression and stability. The F34S mutant is an important 
example: despite having the highest ternary KDMTX reported for any hDHFR mutant (210 
nM), its very poor catalytic efficiency (0.017 µM-1s-1)10 apparently decreases enzyme 
function to a level too low for cellular propagation.  
A diversity of mutations was also observed at position 35 (five out of nine amino 
acids encoded); no resistant point mutants were identified. The Gln35Glu substitution 
occurred in the three most frequently observed selected mutants (figure 2.2), that all 
conserved Phe34. The introduction of a negative charge at this location may introduce 
electrostatic repulsion of the γ-glutamate tail (figure 2.1(b)).While this effect is also 
expected to reduce DHF binding, we note that MTX binding is more importantly reduced 
than productive DHF binding (KMDHF), by a factor of at least 10 (mutant PFE) to more 
than 70 (mutant RFE). The differing binding and kinetic properties of mutants PFE, RFE 
and SFE highlight the impact of combining mutations at position 31 (Pro, Arg or Ser) 
with the Gln35Glu substitution. A positively charged residue at position 35 also supports 
MTX-resistance, as evidenced by the Gln35Arg (mutant RTR) and the Gln35His 
substitutions (mutants AVH and PFH). The side chain of Gln35 has been proposed to 
hydrogen bond with the guanidinium group of Arg70 in the apoenzyme or when the 
ligand does not contain a p-aminobenzoyl function,7,46,47 while in the presence of ligands 
Arg70 forms a conserved salt bridge with the α-carboxylate of the glutamate moiety.12 
The mutations selected at position 35 may render the active site less propitious to ligand 
binding, by forming a Glu35-Arg70 salt-bridge in the apoenzyme or as a result of 
electrostatic repulsion with Arg70 in the case of an Arg35 or His35 mutation. Structural 
data are required to confirm these hypotheses. 
In addition to the correlation of the conserved Phe34 with Q35E, other 
correlations were observed. Mutants PFQ, PFE and PFH equally conserve Phe34 while 
displaying a Phe31 to Pro substitution. Mutants RTR and RTS, two triple mutants, also 
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displayed correlation at positions 31 and 34. In no case was a strict co-variation observed. 
Considering the restricted subset of amino acids encoded at each of the three positions, it 
is likely that greater sequence diversity at positions 31, 34 and 35 can promote resistance.  
How effective is the accumulation of mutations in providing increased MTX 
resistance? Combining the F31P substitution with mutations at position 35 (mutants PFE 
and PFH) resulted in a six-to seven-fold increase in KiMTX  accompanied by a five-to 
seven-fold decrease in catalytic efficiency (table 2.4). Double mutant GFN displayed a 
nearly 40-fold increase in KiMTX and a tenfold decrease in catalytic efficiency relative to 
the point mutant F31G, contributed mainly by a sixfold increase in KMDHF.14 The point 
mutant F31S14 provides only modest MTX-resistance; the addition of mutation Q35E 
(mutant SFE) resulted in a 125-fold increase in KiMTX. In counterpart, the catalytic 
efficiency was reduced sixfold relative to F31S, due solely to decreased DHF affinity. 
The same Q35E mutation had a smaller effect when combined with mutation F31R 
(mutant RFE; table 2.4). Comparison of these double mutants highlights the complexity 
of cumulating active-site mutations: the effect of mutation Q35E differs according to its 
environment (i.e. the amino acid at position 31).  
The selected triple mutants provided further evidence of the impact of multiple 
mutations on resistance: the most highly MTX-resistant hDHFR variants were all triple 
mutants (table 2.2; figure 2.3). While the F31R point mutant alone provides good MTX 
resistance (KiMTX = 7.2 nM)41, additional mutations increased resistance, as evidenced by 
triple mutants RTS (KiMTX = 59 nM) and RTR (KiMTX = 86 nM). The frequently observed 
F31R appears to provide a good basis for further mutations to increase resistance.  
The current data set is consistent with synergistic effects of many of the mutations 
toward MTX binding, as opposed to additive effects.48 A striking example is triple 
mutant AVH, which displayed the weakest MTX binding out of the selected mutants 
(KiMTX = 180 nM), an almost 6000-fold increase in KiMTX relative to the WT. This 
combinatorial mutant nearly matches the best-reported KDMTX (F34S = 210 nM).10 
However, it boasts a catalytic efficiency that is almost 20-fold superior to the F34S point 
mutant. The point mutant Q35H was not selected, suggesting that it does not confer a 
high level of resistance. Nonetheless, Q35H increased the KiMTX of the point mutant F31P 
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in mutant PFH; combined with F31A (KiMTX = 0.27 nM)14 and F34V (KiMTX = 10 nM)10, it 
contributed to the highest resistance in mutant AVH. In a similar fashion, the Q35R 
mutation (the murine Q35R mutant displays only a tenfold increase in KiMTX),17 combined 
with F31R (KiMTX = 7.2 nM)41 and F34T (KiMTX = 9.6 nM),10 contributed to resistance in 
mutant RTR (KiMTX = 86 nM). No resistant triple mutant was identified that was only one 
mutation away from a characterized double mutant, precluding a direct assessment of the 
effect of one additional mutation in these cases. It is not currently possible to predict 
synergistic effects of mutations on specific protein functions; our success in identifying 
multiple active-site environments providing the desired properties resulted from 
searching an area of sequence space that was likely, according to prior knowledge, to 
harbour positive solutions. Despite the fact that F34 was highly conserved during 
selection, likely as a result of its role in DHF binding, mutations at this position in the 
context of neighbouring mutations provided the highest level of resistance. We are 
currently combining this triply-mutated library with further libraries mutated at active-
site residues previously shown to specifically interact with MTX, to attempt to further 
increase MTX resistance while maintaining catalytic efficiency. Rather than restricting 
the identity of mutations to specific point mutants known to confer resistance, each 
position encodes a variety of amino acids, allowing for the possibility of unpredicted 
combinatorial effects. 
As made evident above, the trade-off to decreased MTX binding with the greater 
number of mutations was a general correlation with decreased catalytic efficiency. The 
most important contributor to decreased catalytic efficiency was decreased productive 
binding of DHF: the variation in KMDHF was 1.5 to 44-fold greater than the change in kcat. 
Surprisingly, while the impact of point mutations at positions 31 and 34 on KMDHF was 
great, there was no significant further increase of KMDHF upon accumulating mutations. 
The additional mutations did, however, greatly increase KiMTX. These differences in the 
effect of the mutations toward either ligand may result from the different binding modes 
for the pteroyl moiety of DHF and MTX at the active site of hDHFR (figure 2.1), despite 
the fact that residues 31 and 35 do not directly interact with the pteroyl moiety. We are 
currently testing further ligands of DHFR to verify whether there is a relation between the 
decreased MTX and DHF affinity, and affinity for other ligands. Trimethoprim (TMP), 
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an antibiotic that targets bacterial DHFR with a high degree of specificity (KiTMP E. coli 
DHFR: 80 pM) binds hDHFR 12,000-fold more weakly,49 justifying its use in our 
selection strategy to knock out background E. coli DHFR activity. While most of the 
mutants selected for MTX resistance showed no change of in vitro resistance to TMP 
relative to the WT hDHFR, double mutant RFE and triple mutants RTR and RTS showed 
significant resistance (data not shown). Our results are consistent with the observation 
that the Leu28Arg substitution in E. coli, homologous to hDHFR mutation Phe31Arg, 
contributes to TMP-resistance in addition to MTX resistance. 
The AVH mutant bound to MTX was created in silico to gain insight into the 
effects of the mutations on MTX binding (figure 2.5). While this simple molecular 
visualization does not provide structural evidence, it is clear that the combinatorial 
F31A/F34V mutations enlarge the volume of the active-site cavity proximal to MTX, 
simply as a consequence of the smaller volumes of the substituted amino acids.50 The 
F31A mutation is likely to reduce van der Waals interactions with the p-ABA moiety of 
MTX relative to the WT. The F34V mutation likely has a similar effect in addition to 
reducing van der Waals interactions with the pterin moiety. The effect of the Q35H 
mutation is not as apparent in this visualization. We are presently obtaining structural 
information for mutant AVH by X-ray crystallography.    
We have shown that CHO dhfr- cells containing double mutants RFE or SFE and 
triple mutants RTS or AVH were all protected, to some extent, from the toxic effects of 
MTX (table 2.3; figure 2.4). The positive control, point mutant L22Y, confers good 
MTX-resistance in mammalian cells as a result of its good catalytic efficiency (12 s-1µM-
1) and high KiMTX (10.9 nM).15 Previously reported transfections of hDHFR point mutants 
(F31S, F34S, G15W and L22R) in CHO dhfr- cells43,44 yielded between 2 to 7% cell 
survival in presence of 1 μM MTX. In our similar system, the resistance conferred by our 
double mutants was greater than that for any of the point mutants. In turn, the triple 
mutants offered a better protection than the double mutants. The triple mutant AVH, 
exhibiting the highest KiMTX, conferred the best protection with 70% cell survival at 200 
μM MTX, despite the fact that it displayed the lowest catalytic efficiency among our 
sample. This suggests that weak MTX binding is a more important feature than catalytic 
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efficiency in protecting the CHO cells. This result provides an interesting tool for further 
increasing MTX resistance, given that most MTX-resistant mutants previously used to 
protect mammalian cells had catalytic efficiencies at least tenfold higher than the AVH 
mutant.51   
Combining active-site mutations in hDHFR yielded novel insights concerning 
increased MTX resistance. Ideally, one would like to predict the capacity of a mutant to 
confer MTX resistance to mammalian cells from assessment of a specific in vitro 
parameter, be it KiMTX, IC50MTX or KDMTX, or yet a combination such as KiMTX × catalytic 
efficiency.10,14,16 While each of these provided a rough estimate of resistance, we did not 
succeed in ranking the in vivo effect of the MTX resistant mutants according to in vitro 
parameters. We believe factors such as expression level, folding, stability and cell type all 
contribute to the in vivo effect. Given the correlation between the efficiency of MTX-
protection in CHO dhfr- and in haematopoietic stem cells for a given MTX-resistant 
mutant,43,52 we are currently investigating the potential for the most highly MTX-resistant 
combinatorial mutants to protect haematopoietic stem cells, via retroviral infections. 
Preliminary results in haematopoietic stem cells (J.P.V. et al., unpublished results) 
suggest that, despite the fact that mutant AVH confers a high level of MTX-resistance, it 
is not our most effective mutant at conferring resistance in that specific in vivo context. 
This underscores the difficulty of identifying an in vitro indicator for ranking in vivo 
effects, and supports further identification of a variety of MTX-resistant hDHFR variants 
for application in different contexts.    
 
MATERIALS AND METHODS 
Reagents 
Restriction and DNA modifying enzymes were purchased from MBI Fermentas 
(Burlington, ON). Folic acid, methotrexate, β-NADPH, adenine, deoxyadenine and 
thymidine were purchased from Sigma-Aldrich (Oakville, ON). Dihydrofolic acid (DHF) 
was synthesized from folic acid as described.53 Ni-NTA was purchased from Qiagen 
(Mississauga, ON). Cell culture media and reagents were purchased from Invitrogen 
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(Burlington, ON), with the exception of dialyzed fetal bovine serum (FBS), which was 
obtained from HyClone (Logan, UT), and 5-bromo-4-chloro-3-indoyl-β-D-
galactopyranoside (X-Gal), which was purchased from US biological (Swampscott, MA). 
CHO DUKX B11 (dhfr-) cells were a generous gift from Ingrid Remy and Stephen W. 
Michnick (Université de Montréal, Montréal, QC).   
Bacterial strains and plasmids  
 E. coli strain SS320 was used for propagation of the DNA library.54 E. coli strain 
SK037,39 which was used for selection and over-expression of MTX-resistant mutants, 
was a generous gift from Gwen S. Snapp and James C. Hu (Texas A&M University, 
College Station, TX). The pQE32 expression vector was purchased from Qiagen. The 
WT hDHFR (MRA-91) and hDHFR L22Y (MRA-90) genes contained in pBluescript 
vector55 were obtained from the Malaria Research and Reference Reagent Resource 
center (Manassas, VA). 
Oligonucleotides and DNA constructions  
 Standard oligonucleotide primers used for mutagenesis were purchased from 
Alpha DNA (Montréal, QC). Primers containing degenerate codons were purchased from 
Integrated DNA Technologies (Coralville, IA). Dye-labelled oligonucleotide primers for 
DNA sequencing were purchased from Li-Cor Biotechnology (Lincoln, NB).  The 
external primer set 1 (primer 1A: fwd 5' 
ACACACGGATCCAAATGGTTGGTTCGCTAAACTGCATC (BamHI restriction site 
in italics) and primer 1B: rev 5' CAATTTCACACAGGAAACAGCT) was designed for 
PCR amplification of the entire coding region of the WT hDHFR and hDHFR L22Y 
genes and subcloning into pQE32 vector between the BamHI and HindIII restriction 
sites. An AflII restriction site (in italics) was introduced for ulterior recombination work 
via silent mutations between codons 26 and 28 of WT hDHFR by mega-primer PCR,56 
using primer 2: rev 5' 
TGGAAATATCTAAATTCGTTCCTTAAGGGTGGCCACGGCAGGT and the external 
primer set 1. The resulting construct, WT hDHFR-pQE32, expressed WT His6-hDHFR 
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(N-terminally His6-tagged) and served as a template for the creation of the hDHFR 
mutant library as well as for the creation of eukaryotic transfection DNA constructs.  
Creation of the hDHFR mutant library at positions Phe31, Phe34 and Gln35  
 The hDHFR mutant library was created by megaprimer PCR,56 using degenerate 
primers encoding a variety of amino acids at positions Phe31, Phe34 and Gln35 (see 
table 2.1) using primer 3: rev 5' 
AGAGGTTGTGGTCATTCTSYBKRHATATCTGVVTTCGTTCCTTAAGGGTGG 
(degenerate codons in italics) as well as primer 1A and primer 4B: rev 5' 
GTTCTGAGGTCATTACTGG as external primers (external primer set 2). The resulting 
library was cloned into pQE32 using the BamHI and HindIII restriction sites and 
transformed in E. coli SS320, yielding approximately 1 × 104 colonies. The quality of the 
library was evaluated by sequencing the entire hDHFR gene from 70 colonies picked on 
Luria-Bertani (LB) medium containing 100 µg/mL ampicillin (LA-100; non-selective 
conditions). Sequencing was performed by the dideoxy-chain termination method using a 
Thermo Sequenase Cycle Sequencing kit (GE Healthcare, Piscataway, NJ) and a dye-
labelled primer with a Li-Cor 4200 automated sequencer (Lincoln, NB). 
Selection and identification of highly MTX-resistant mutants  
Plasmid DNA from the pooled hDHFR mutant library was isolated and 
transformed into electrocompetent E. coli SK037 cells for selection. The cells were plated 
in equal dilutions on LA-100 (non-selective) or on M9 minimal medium containing 
0.08% (w/v) casamino acids, 100 µg/mL ampicillin, 1 µg/mL trimethoprim (TMP) and 1 
mM MTX (dissolved in 0.05M KOH) (ATM-1000 medium; selective conditions). 
Colony formation took place at 37°C for 16 hrs on the non-selective medium and for 36 
hrs on the selective medium. The survival rate of the library was calculated from the ratio 
of colonies formed on selective ATM-1000 relative to non-selective LA-100 medium. 
Seventy colonies were picked on ATM-1000 media, and the plasmid DNA was 
sequenced to identify mutations at positions 31, 34 and 35. In all cases, the entire coding 
sequence was verified.  
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Expression and purification of selected hDHFR variants  
For expression of both WT His6-hDHFR and MTX-resistant mutants identified by 
selection, the plasmids of interest were isolated and retransformed into E. coli SK037 
cells. Overnight cultures were used to inoculate 50 mL of LB media and were propagated 
at 37°C until A600 nm ≈ 0.7. Protein expression was induced with the addition of 1 mM 
isopropyl 1-thio-β-D-galactopyranoside (IPTG), after which cells were further 
propagated for 3 hrs at 37°C. Induced cells were harvested by centrifugation (4000g for 
30 min at 4°C). The cell pellet was resuspended in 0.1M potassium phosphate buffer (pH 
8.0), 5 mM imidazole. The cells were lysed on ice using a Branson sonicator (three pulses 
at 200 W for 30 s with a tapered micro-tip). Cellular debris were pelleted by 
centrifugation (4000g for 30 min at 4 °C) and 1 mL of pre-equilibrated Ni-NTA resin 
(Qiagen) was added to the supernatant. The slurry was mixed by inversion at 4°C for 1 h, 
after which it was transferred to a column (Bio-Rad Polyprep Chromatography columns, 
0.8 x 4 cm) for gravity-flow purification. The column was washed with 5 mL each of 
0.1M phosphate buffers (pH 8.0) containing increasing concentrations of imidazole (5, 
10, 15 and 20 mM). Elution of bound protein was achieved using 2 mL of 0.1M 
phosphate buffer (pH 7.5), 50 mM imidazole. Eluted protein was dialyzed overnight 
against 0.1M phosphate buffer (pH 7.5) at 4°C for 16 hrs. Expression pattern and purity 
of enzymes were evaluated using the public domain image analysis software Scion Image 
(NIH, rsb.info.nih.gov/nih-image) following separation by  SDS-PAGE (15% (w/v) 
polyacylamide gel) stained by the zinc-imidazole method.57 Protein concentration was 
determined using the Bradford assay (Bio-Rad, Hercules, CA).  
Determination of kinetic and inhibition parameters 
All kinetic and inhibition assays were conducted in MATS buffer (25 mM Mes, 
25 mM acetate, 50 mM Tris, 100 mM sodium acetate and 0.02% (w/v) sodium azide) (pH 
7.6) at 23°C. Substrates were dissolved in MATS buffer and quantified by 
spectrophotometry (ε340 nm = 6200 M-1cm-1 for NADPH and ε282 nm = 28,400 M-1cm-1 for 
DHF). MTX was dissolved in 0.05M KOH and quantified by spectrophotometry in 0.1M 
NaOH using ε258 nm = 22 100 M-1cm-1 and ε302 nm = 23 300 M-1cm-1. Kinetic parameters for 
the hDHFR mutants were determined with a Cary 100 Bio UV/Vis spectrophotometer 
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(Varian Canada Inc., Montréal, QC) by monitoring the NADPH and DHF depletion 
(Δε340 nm = 12 800 M-1cm-1)58 in 1-cm cells with 10 nM enzyme, unless otherwise stated. 
All assays were performed in at least 4 independent experiments and the average values 
are reported. The initial rates during the first 15% of substrate conversion were recorded 
for all assays. Kinetic and inhibition parameters were obtained from a non-linear 
regression fit to the Michaelis-Menten equation using Graphpad Prism (Graphpad 
Software, San Diego, CA). The kcat values were determined in presence of saturating 
substrate concentrations (100 µM each of DHF and NADPH) in 1-cm cells according to 
kcat = Vmax/[E]. KM values for DHF (KMDHF) for the MTX-resistant mutants were 
determined in presence of 20 µM NADPH by varying the concentration of DHF (0.5 µM 
to 20 µM). For WT His6-hDHFR, KMDHF was obtained by spectrophotometric 
determination in 10-cm cells containing 1 nM enzyme, 10 µM NADPH and a range of 
DHF concentrations (0.05 µM to 10 µM). The kinetic parameters of two mutants 
determined in 1-cm cells were also confirmed in 10-cm cells. IC50MTX for WT His6-
hDHFR and mutants were determined in presence of saturating concentrations of 
substrates (100 µM each of DHF and NADPH) and increasing concentrations of MTX 
(0.025 µM to 100 µM). Inhibition constants for MTX (KiMTX) were calculated from the 
determined IC50MTX according to the equation for competitive inhibitor binding.59 
Determination of equilibrium dissociation constants  
Ternary equilibrium dissociation constants for MTX (KDMTX) were determined in a 
1-cm path-lenght quartz cell using a Cary Eclipse Bio fluorometer (Varian Canada Inc., 
Montréal, QC), by titrating the fluorescence quenching resulting from formation of the 
enzyme-ligand complex with increasing concentrations of MTX. For each variant tested, 
enzyme and NADPH were mixed at final concentrations of 200 nM and 5 μM (saturating 
concentration), respectively, and serial additions of MTX were added (0 to 1600 nM) in a 
final volume of 3 mL. The total volume of added MTX represented approximately 10% 
of the entire sample volume. After each addition of MTX, the solution was mixed with a 
magnetic stirrer for 2 minutes. Fluorescence quenching was monitored at λex = 280 nm 
and λem = 435 nm. All assays were performed in at least 3 independent experiments, and 
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the average values are reported. The KDMTX values for each variant were obtained by 
fitting relative fluorescence (ΔF ) to the following equation:60 
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Molecular modelling  
Molecular modelling was performed using the InsightII package (version 2000, 
Accelerys), with 1U72.pdb (WT hDHFR with bound MTX and NADPH)7 as starting 
coordinates. Following removal of the crystallographic water molecules, the 
BIOPOLYMER module was used to mutate residues 31, 34 and 35 and to add hydrogen 
atoms at the normal ionization state of amino acids at pH 7. Energy minimization of the 
enzyme-ligand complex was performed using 1000 steps of steepest descents 
minimization, followed by a conjugate gradient minimization until convergence of 0.001 
kcal/mol/Å. Minimizations were performed with no constraints, using a dielectric 
constant of 80 and a cut-off value of 100 Å.  
Protection of eukaryotic cells with MTX-resistant hDHFRs  
Genes encoding the MTX-resistant mutants with the highest KiMTX values were 
amplified by PCR with primer 5A: fwd 5' 
ACACACGAATTCATCCACCATGGTTGGTTCGCTAAACTGCAT and primer 5B: rev 
5' ACACACCTCGAGAGCTTAATCATTCTTCTC and sub-cloned into pcDNA3.1 (+)-
Zeo (Invitrogen) using the EcoRI and XhoI restriction sites (in italics). The WT and 
L22Y hDHFR genes were also amplified and cloned as described above, to serve as 
negative and positive controls for MTX resistance, respectively. The resulting constructs 
do not encode a His6 tag. A mock transfection with pcDNA3.1 (+)-Zeo also served as a 
negative control. Cells were stained using trypan blue and counted using a Bright-Line 
hemacytometer (American Optical Corporation, Buffalo, NY). CHO DUKX B11 cells 
were propagated at 37°C, 5% CO2 (v/v) in 10-cm plates and passaged every 48 h at 1.5 × 
106 cells per plate in α-MEM containing 10% (v/v) dialyzed FBS, 4 mM glutamine, 10 
µg/mL each of adenine, deoxyadenosine and thymidine, 100 units/mL penicillin and 100 
µg/mL streptomycin (complete α-MEM medium). For passages, cells were washed twice 
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with 1 × PBS and trypsinized for 5 min at 37 °C. Before transfection, 5 × 105 cells at 
passage 10 or less were propagated for 18 h on 10-cm plates (70% confluence). A 3µg 
sample of plasmid DNA was mixed with 20 µL of Lipofectamine 2000 (Invitrogen) and 
incubated at room temperature for 45 min in 800 µL Opti-MEM. The mixture was added 
to the cells, which were further incubated at 37 °C with 5% CO2 for 4 h. The transfection 
media was replaced by α-MEM media for 36 h. The transfected cells were split into 6 cm 
plates containing approximately 1 × 105 cells. The cells were exposed to different 
concentrations of MTX (0 - 200 µM) in α-MEM media in the absence of adenine, 
deoxyadenine and thymidine. As a reference, the same number of cells was plated in 
complete α-MEM medium. The stock solution (2 mM MTX) was prepared in 0.05M 
KOH to ensure dissolution; MTX could not be added at a higher concentration than 200 
µM as this marked the limit of the buffering capacity of the medium. The cells were 
counted after 48 h. Transfection efficiency was evaluated first by transfecting the lacZ 
reporter gene (pBabe-LacZ)61 and by counting the number of blue cells in the presence of 
X-Gal; and secondly by comparing the number of cells in absence and in presence of 
nucleotides in the media. The percentage of cell survival is given as the ratio of cells 
counted in the presence or in the absence of MTX (in absence of nucleotides). EC50MTX 
were generated with a non-linear sigmoidal fit using Graphpad Prism software. All MTX-
resistance studies were performed in at least 3 independent experiments and the average 
EC50MTX values are reported. Expression of hDHFR variants was verified by Western 
blotting, following resolution of supernatant from transfected CHO DUKX B11 cells by 
SDS-PAGE (15% (w/v) polyacrylamide gel) and semi-dry transfer on PVDC membrane. 
The membranes were blocked with 5% (w/v) powdered milk before overnight incubation 
at 4 ºC with primary polyclonal anti-mDHFR antibody from rabbit. Membranes were 
washed twice with PBS, 0.5% (v/v) Tween before incubation for 1 h at 4 °C with the 
secondary monoclonal anti-rabbit-alkaline phosphatase coupled antibody (Sigma-
Aldrich). Protein bands were revealed with BCIP/NBT (Sigma-Aldrich) for 10 min at 
room temperature.    
  
70
Table 2.1. Amino acids encoded at residues 31, 34 and 35 of the hDHFR mutant 
library 
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Table 2.2. Kinetic and inhibition constants for the selected MTX-resistant hDHFR 
mutants 
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Table 2.3. EC50 MTX for CHO DUKX B11 cells transfected with MTX-resistant 
hDHFR mutants 
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Table 2.4. Comparison of MTX-resistant hDHFR mutated at positions F31 and F34 
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Figure 2.1. Ligand binding at the active-site of WT hDHFR. A: Superimposition of 
hDHFR with bound folate (yellow; 1DRF.pdb62) and its competitive inhibitor 
methotrexate (red; 1U72.pdb7). The active site is shown, highlighting the flip of the 
bicyclic pteroyl ring. Stick representations of side-chains from Ile7, Leu22, Trp24, 
Glu30, Arg70 and Val115 are shown in white. The residues targeted for mutation, Phe31, 
Phe34 and Gln35, are in green. A conserved active-site water molecule is depicted as a 
red sphere. B: Hydrogen bonding network of bound MTX at the active site of hDHFR. 
Side-chains and MTX are in sticks representation, coloured by atom (nitrogen (blue), 
oxygen (red) and carbon (white for side chains and green for MTX)). A conserved active-
site water molecule is depicted as a red sphere. For clarity, only the coordinates of 
1U72.pdb are represented.  
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Figure 2.2. Frequency of occurrence of the novel MTX-resistant mutants. Seventy 
mutants were isolated following selection of the hDHFR mutant library on ATM-1000 
medium. Mutants are designated by the one-letter code of the amino acid occurring at 
positions 31, 34 and 35, respectively. Mutant PFQ corresponds to point mutant F31P. 
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Figure 2.3. Relation between the number of hDHFR mutations and kcat/KMDHF or 
KiMTX relative to WT His6-hDHFR. Mutants are designated by the one-letter code of the 
amino acid occurring at positions 31, 34 and 35, respectively. Numbers in parentheses 
correspond to the number of mutations in the variant. Log kcat/KMDHF relative to WT is 
shown in grey while log KiMTX relative to WT is in black. 
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Figure 2.4. Survival of CHO DUKX B11 cells transfected with selected mutants in 
presence of MTX. Data is presented for two representative mutants: double mutant SFE 
(         ) and triple mutant AVH (         ). The positive control L22Y (          ) and the 
negative control WT hDHFR ( .     ) are given as references. SFE and AVH are 
designated by the one-letter code of the amino acid occurring at positions 31, 34 and 35, 
respectively. Percentage of cell survival represents the ratio of cells counted in presence 
and absence of MTX after 48hrs at 37ºC, 5% CO2. 
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Figure 2.5. In silico comparison of MTX binding between (A) WT hDHFR (1U72) 
and (B) mutant AVH. Protein structures are shown in surface representation with 
residues 31, 34 and 35 coloured yellow, and MTX coloured by atom (nitrogen, blue; 
oxygen, red; and carbon, green), in sticks representation. AVH coordinates were obtained 
by mutating residues 31, 34, 35 using PDB file 1U72 as starting coordinates, followed by 
minimization in presence of bound MTX and NADPH. NADPH is not shown. 
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Chapter 3 (Article 2) – Two-tier bacterial and in vitro 
selection of active and methotrexate-resistant variants 
of human dihydrofolate reductase 
 
Section 3.0 – Preface 
Article 2 describes the development of an efficient and rapid screening strategy to 
identify active and antifolate resistant mutants of hDHFR. Moreover, the article provides 
new information regarding the specific role of key active-site residues in binding. 
Five little characterized active-site positions (Ile7, Gly15, Trp24, Arg70 and 
Val115) were individually mutated by saturation mutagenesis, creating small libraries (20 
mutants/library) suitable for further methodological development.  
The selection strategy described in chapter 2 (article 1) was sufficiently efficient 
to identify highly MTX-resistant mutants. However, bacterial survival under selective 
conditions (high concentration of MTX in this specific case) is not a direct read-out of 
catalytic activity in vitro. In fact, factors like expression level, solubility and stability can 
be compatible with minimal activity in an in vivo context (and therefore with bacterial 
propagation), but inadeguate for in vitro characterization. As a result, it may not be 
possible to discriminate among the variety of good and mediocre positive hits from the 
selection. In order to optimize the screening process for larger-scale application (analysis 
of large-size libraries of mutants) a lower throughput but more informative second-tier in 
vitro assay was added to screen all positive hits from bacterial selection. The assay 
consisted in measuring residual enzymatic activity in the presence of a concentration of 
inhibitor which is user-defined, where a higher concentration provides more stringent 
screening. The in vitro assay was performed directly from cell lysates (with no need for 
purification) using a plate reader, and also allowed determination of a quantitative 
descriptor for MTX-resistance (IC50MTX).  
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Moreover, we extended the flexibility of our directed evolution approach by 
developing a two-tier selection strategy for detection of activity (which requires DHF 
binding) and resistance to the antifolate pemetrexed (which requires reduced binding of 
the inhibitor), demonstrating the broad applicability of the strategy for studying binding 
of different compounds at the active-site of hDHFR. 
I was responsible of the majority of the experimental work. Joelle Pelletier and I 
were responsible of the design of the experimental approach and the edition of the paper. 
Jordan Volpato was responsible of the choice of the active-site residues to be mutated, 
the creation of 2 of the 5 libraries of mutants created, the creation of figure 1 and of 
critical discussion both related to the experimental work and to the edition of the paper. 
Lucie Poulin performed half of DNA sequencing. David-Antoine Dugas created library 
115 under my supervision. Vanessa Guerrero performed part of the screening (screening 
for activity and MTX-resistance of libraries 15 and 24 and part of the screening for 
pemetrexed resistance) under my supervision.  
 
An erratum corrigendum about the kinetic and inhibition parameters of one of the 
hDHFR mutants characterized was added to the chapter, right after the references section. 
  
89
2-TIER BACTERIAL AND IN VITRO SELECTION OF 
ACTIVE AND METHOTREXATE-RESISTANT VARIANTS 
OF HUMAN DIHYDROFOLATE REDUCTASE 
 
Elena Fossati, Jordan P. Volpato,1 Lucie Poulin,2  Vanessa Guerrero,1 
David-Antoine Dugas1 and Joelle N. Pelletier1,2 
 
 
1Département de biochimie and 2Département de chimie 
 Université de Montréal 
C.P. 6128, Succursale Centre-ville 
Montréal (Québec) 
 H3C 3J7, CANADA 
 
 
J. Biomol. Screen., 2008, 13 (6), 504-514 
 
 
Reprinted with permission from: Jordan P. Volpato, Lucie Poulin, Vanessa Guerrero, 
David-Antoine Dugas and Joelle N. Pelletier. “2-tier bacterial and in vitro selection of 
active and methotrexate-resistant variants of human dihydrofolate reductase” J. Biomol. 
Screen., 13 (6), 504-514. Copyright (2008), with permission from the Society for 
Biomolecular Sciences. 
 
  
90
ABSTRACT 
We report a rapid and reliable 2-tier selection and screen for detection of activity 
as well as drug-resistance in mutated variants of a clinically-relevant drug-target enzyme. 
Human dihydrofolate reductase point-mutant libraries were subjected to a 1st-tier 
bacterial complementation assay, such that bacterial propagation served as an indicator of 
enzyme activity. Alternatively, when selection was performed in the presence of the 
inhibitor methotrexate (MTX), propagation indicated MTX resistance. The selected 
variants were then subjected to a 2nd-tier in vitro screen in 96-well plate format using 
crude bacterial lysate. Conditions were defined to establish a threshold for activity or for 
MTX resistance. The 2nd-tier assay allowed rapid detection of the best variants among 
the leads and provided reliable estimates of relative reactivity, (kcat) and IC50MTX. 
Screening saturation libraries of active-site positions 7, 15, 24, 70 and 115 revealed a 
variety of novel mutations compatible with reactivity as well as 2 novel MTX-resistant 
variants: V115A and V115C. Both variants displayed KiMTX = 20 nM, a 600-fold increase 
relative to the wild-type. We also present preliminary results from screening against 
further antifolates following simple modifications of the protocol. The flexibility and 
robustness of this method will provide new insights into interactions between ligands and 
active-site residues of this clinically relevant human enzyme.  
Key words: Human dihydrofolate reductase, methotrexate, drug resistance, saturation 
mutagenesis, high-throughput screening 
 
INTRODUCTION 
Dihydrofolate reductase (DHFR, EC 1.5.1.3) catalyzes the NADPH-dependent 
reduction of 7,8-dihydrofolate (DHF) to 5,6,7,8-tetrahydrofolate (THF), an essential 
metabolite involved in the biosynthesis of purines and thymidylate.1 Due to its crucial 
role in cell proliferation, human DHFR (hDHFR) has long been a target in the treatment 
of psoriasis,2 rheumatoid arthritis2,3 and neoplastic diseases.4 A specific competitive 
inhibitor of hDHFR, the antifolate methotrexate (MTX), has been extensively used to 
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treat various cancers.4 Limitations to cancer treatment with MTX include lack of 
specificity for cancerous cells1  and development of drug resistance.5 
 Among the recognized MTX-resistance mechanisms,5 we are specifically 
interested in mutations that weaken MTX binding. Despite their structural similarity, the 
substrate DHF and the inhibitor MTX bind to the active site in different orientations, 
making different contacts with the enzyme.6,7 Active-site mutations may thus reduce 
MTX binding while maintaining sufficient DHF affinity for catalysis.8-10 Gaining a better 
understanding of substrate and inhibitor binding at the hDHFR active site by 
characterizing ligand binding in active-site variants will offer insight toward the synthesis 
of alternative antifolates.4,10 In a clinical context, MTX-resistant hDHFR variants can 
offer protection of haematopoietic stem cells from the cytotoxicity of MTX via gene 
therapy.11 Furthermore, MTX-resistant hDHFR variants show excellent potential as 
selectable markers for gene transfer in stem cells, improving the outcome of gene 
therapy.11 For these applications, ideal hDHFR variants should possess a high Ki for 
MTX (weak binding) and efficient catalytic properties (low KMDHF and high kcat) in 
addition to good stability, solubility and high expression levels. 
 We previously performed directed evolution to identify highly MTX-resistant 
variants of hDHFR from a combinatorial library of mutants using a rapid bacterial 
selection strategy.8 The strategy relies on the capacity for variants of human DHFR to 
allow bacterial propagation in the presence of high MTX concentrations. While 
characterization of the selected variants confirmed successful identification of active and 
highly MTX-resistant hDHFR variants with no significant background from false-
positive hits, there remain issues to be addressed to allow its broader application. First, 
we need to assess if the bacterial-based selection strategy is robust; that is, what is the 
incidence of false-negatives? While bacterial selection offers the undeniable advantage of 
speed, it is challenging to tune the sensitivity to specific enzyme properties. Differences 
in mutant enzyme stability, expression levels and limitations set by bacterial metabolic 
requirements (upper or lower threshold for requirement of a specific metabolite) 
contribute to phenotypic responses that do not reflect kinetic properties of the enzyme 
variants. Second, classic methods for characterizing the kinetic parameters defining 
activity and MTX-resistance of the selected variants were lengthy and labour-intensive, 
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precluding application at a larger scale. Finally, the selection assay had been designed 
exclusively for the purpose of identifying the phenotype of MTX-resistance. However, a 
further phenotype of interest is that of conservation of native-like activity upon mutation.  
 Herein, we present a streamlined, 2-tier selection and screening protocol to 
rapidly identify hDHFR variants that are active and/or MTX-resistant and that possess 
properties justifying further, more detailed kinetic characterization. As a 1st step, the 
bacterial selection strategy was expanded to select either for native-like activity or for a 
combination of activity and MTX-resistance. Then, an in vitro activity assay was 
conveniently performed directly on cell lysates in 96-well plate format to rapidly provide 
a reliable estimate of catalytic activity and/or MTX-resistance. Toward this goal, active-
site residues 7, 15, 24, 70 and 115 of hDHFR, each known or suspected to affect ligand 
binding, were subjected to saturation mutagenesis. The 5 libraries were selected for 
conservation of native-like activity and for MTX resistance. A variety of mutations 
compatible with activity were identified and 2 novel MTX-resistant variants were 
identified and characterized. Preliminary results from screening against further antifolates 
are also reported, demonstrating the adaptability of the approach. 
 
MATERIALS AND METHODS 
Reagents 
Restriction and DNA modifying enzymes and dNTPs were purchased from MBI 
Fermentas (Burlington, ON). Folic acid, methotrexate (MTX), β-NADPH, trimethoprim 
(TMP), buffers and CelLyticTM B Cell Lysis Reagent were from Sigma-Aldrich 
(Oakville, ON). Pemetrexed (ALIMTA) was from Eli Lilly (Toronto, ON). Alimta was 
supplied as 1:1 mixture of pemetrexed and D-mannitol. Dihydrofolate (DHF) was 
synthesized from folic acid.12 Standard mutagenic oligonucleotide primers were from 
Alpha DNA (Montréal, QC), while primers containing degenerate codons were from 
Integrated DNA Technologies (Coralville, IA). The QIAquick® Gel extraction kit, 
QIAprep® Spin plasmid purification kits, and Ni-NTA agarose were from Qiagen 
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(Mississauga, ON). Isopropyl 1-thio-β-D-galactopyranoside (IPTG) was from BioShop 
Canada (Burlington, ON). DNA sequencing was performed by dideoxy-chain termination 
using a Thermo Sequenase Cycle Sequencing Kit (GE healthcare) and dye-labelled 
primers (fwd 5'CGGATAACAATTTCACACAG3’ or rev 
5’GTTCTGAGGTCATTACTGG3’) (Li-Cor Biotechnology, Lincoln, NB) with a Li-Cor 
4200 automated sequencer. Escherichia coli strain SK03713 was a generous gift from 
Gwen Snapp and James Hu (Texas A&M). 
Creation of the hDHFR saturation mutant libraries 
 The construct WT hDHFR-pQE32 encoding WT human DHFR cloned into 
pQE32 (Qiagen) between the BamHI and HindIII sites was previously described.8 It 
expresses WT His6-hDHFR (N-terminally 6-histidine tagged) and was the template in 
creation of the mutated libraries. The external primer set 1 (primer 1A: fwd 5' 
ACACACGGATCCAAATGGTTGGTTCGCTAAACTGCATC3’ [BamHI restriction site 
underlined]; primer 1B: rev 5’GTTCTGAGGTCATTACTGG3’) allowed for PCR 
amplification of the entire coding region. Libraries 7 and 15, named according to the 
numbering of the mutated residue, were constructed in a single-step PCR using primers 
fwd7 
(5’ACCATGGGATCCAAATGGTTGGTTCGCTTAACTGCNNSGTCGCTGTGTC 
CCAGA3’; a silent mutation [bold] was introduced as a tracer) or fwd15 
(5’ACCATGGGATCCAAATGGTTGGTTCGCTAAACTGCATCGTCGCTGTGTCCC
AGAACATGNNSATCGGCAAGAACGG3’), respectively, with primer 1B. Library 24 
was constructed by 2-step megaprimer PCR14 using primer 24 (rev 
5’TCCTTAAGGGTGGSNNCGGCAGGTCCCCGT3’) and external primer set 1. 
Libraries 70 and 115 were created by 3-step overlap extension PCR15 using primers 70A 
(fwd 5’CGACCTTTAAAGGGTNNSATTAATTTAGTTAG3’) and 70B (rev 
5’CTGAGAACTAAATTAATSNNACCCTTTAAAGGTCG3’) or primers 115A (fwd 
5’GACATGGTCTGGATANNSGGTGGCAGTTCTGTTTATAAGG3’) and 115B (rev 
5’CCTTATAAACAGAACTGCCACCSNNTATCCAGACCATGTC3’), and the external 
primer set 1. Degenerate codons are underlined. The resulting libraries were cloned into 
pQE32 between BamHI and HindIII and transformed into electrocompetent E. coli 
  
94
SK037, yielding approximately 1 × 104 colonies per library. The quality of each library 
was verified by sequencing DNA from clones propagated on LB agar containing 100 
µg/ml ampicillin.  
Selection for activity and MTX resistance 
Library-transformed E. coli SK037 was selected first for hDHFR activity, then for 
MTX resistance. E. coli SK037 transformed with pQE2 (Qiagen) was the negative 
control. Cells were plated in equal dilutions on M9 minimal agar containing 0.08% w/v 
casamino acids and 100 µg/ml ampicillin (MM_A; non-selective conditions), on MM_A 
containing 0.1 µg/ml trimethoprim (TMP) (MM_AT; selective conditions for hDHFR 
activity) and MM_AT containing 1 mM MTX (ATM_1000;8 selective conditions for 
MTX resistance). Colony formation took place at 37 °C over 18 h on both MM_A and 
MM_AT and over 22 h on ATM_1000. The survival rate for each library was the ratio of 
colonies observed on selective MM_AT or ATM_1000 relative to non-selective MM_A 
medium. Following selection, plasmid DNA was sequenced to identify the mutations at 
the targeted positions. In all cases, the entire coding sequence was verified, and in certain 
cases, both strands were verified.  
Protein expression and cell lysis 
For expression, transformed E. coli SK037 were propagated in LB (100  µg/ml 
ampicillin) at 37 °C, 225 rpm in 96-well assay blocks with 2 ml wells (Costar, 
Cambridge, MA). Fresh LB medium (1 ml) was inoculated with overnight cultures (25 
μl) and propagated until OD600 ≈ 0.6. Protein expression was induced by addition of 
IPTG to a final concentration of 1 mM and further propagation for 3 hrs. The assay 
blocks were centrifuged (30 min, 2700 × g, 4 °C), the supernatant was removed and the 
pellets were resuspended in 150 μl of lysis reagent (15 min, 225 rpm, room temperature). 
The lysates were clarified by centrifuging as above and were preserved on ice until 
required. 
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Determination of activity and antifolate resistance from crude cell lysates in 96-well 
plates 
All rate measurements were in MATS buffer (25 mM MES, 25 mM acetic acid, 
50 mM Tris, 100 mM sodium acetate and 0.02% w/v sodium azide) pH 7.6, 23 °C. 
Substrates were dissolved in buffer and quantified by spectrophotometry (ε340 nm = 6 200 
M-1cm-1 for NADPH; ε282 nm = 28 400 M-1cm-1 for DHF). MTX was dissolved in 0.05 M 
KOH and quantified in 0.1 M NaOH (ε258 nm = 22 100 M-1cm-1 and ε302 nm = 23 300 M-
1cm-1). Pemetrexed (ALIMTA) was dissolved and quantified in 0.9 % w/v NaCl (ε226 nm = 
31200 M-1cm-1). Catalytic activity of mutants was determined in 96-well flat-bottom 
plates (Costar #3595, Cambridge, MA) with a FLUOstar OPTIMA UV-Vis plate reader 
(BMG Laboratories, Offenburg) by monitoring concurrent NADPH and DHF depletion 
(Δε340 nm = 12 800 M-1 cm-1).16 Reaction rates were determined in a final volume of 300 
µl using crude cell lysate and 100 µM each DHF and NADPH. To evaluate the 
background due to bacterial DHFR, reactions were conducted in presence or absence of  
1 μg/ml TMP. 
To ensure high signal to background while keeping the reaction sufficiently slow 
to allow measurement of initial rates, an initial estimate of reaction rate was obtained 
using various dilutions of the lysates. The dilutions were then adjusted for rate 
measurement of each variant. These dilutions were also used for determination of kcat 
according to kcat = Vmax / [hDHFR], where the concentration of soluble hDHFR variant in 
each lysate was estimated following migration on 15 % SDS-PAGE and Coomassie blue 
staining. Protein quantification was performed using the image analysis software Scion 
Image (NIH, rsb.info.nih.gov/nih-image) from digitalized images of the stained gels.  
For assessment of MTX resistance, residual activities were determined as the ratio 
of activity in presence of 200 or 1000 nM MTX versus activity in absence of MTX. The 
concentration of hDHFR variant in each lysate was verified to ensure that saturating 
concentrations of MTX were used. For library 115, the approximate  IC50MTX values of 
active mutants were determined from cell lysates by monitoring initial reaction rates in 
presence of 100 µM each DHF and NADPH and increasing concentrations of MTX: 0, 
50, 500, 1000, 5000 and 10000 nM. IC50MTX values were obtained from a non-linear 
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regression fit to the hyperbolic model for one-site binding using Graphpad Prism 
(Graphpad Software, San Diego, CA) and the data from three independent experiments. 
For assessment of PMTX resistance, residual activities were determined as the 
ratio of activity in presence of 5 μM or 20 μM PMTX versus activity in absence of 
PMTX. For assessment of TMP sensitivity, reactions were conducted in presence or 
absence of 0.1 μg/ml (0.34 µM) and 1 μg/ml (3.4 µM) TMP. 
Purification and characterization of individual selected variants 
The MTX-resistant and the PMTX-resistant mutants identified by screening as 
well as mutant I7F were expressed and purified by Ni-NTA affinity chromatography as 
previously described8 from 50 ml of culture medium. Solubility and relative expression 
level were verified by loading volume-equivalent amounts of total cell extracts, cell pellet 
and lysis supernatant for resolution by 15 % SDS-PAGE. Purity was evaluated using the 
Scion Image software following separation by 15 % SDS-PAGE and Coomassie blue 
staining. Protein concentration was determined using the Bradford assay (Bio-Rad, 
Hercules, CA). Kinetic and inhibition constants were determined in presence DHF and 
NADPH (100 µM each) in 1-cm cells with a Cary 100 Bio UV/Vis spectrophotometer 
(Varian Canada, Montréal, QC).8 For determination of KMDHF, the concentration of DHF 
was varied (0.5 µM to 20 µM).  For determination of IC50MTX, the following MTX 
concentrations were used: 0, 0.025, 0.050, 0.1, 0.5, 1, 10 μM. For determination of 
IC50PMTX, the following PMTX concentrations were used: 0, 0.1, 0.5, 1, 5, 10, 100 μM. 
KiMTX and KiPMTX were calculated from IC50MTX and IC50PMTX, respectively, according to 
the equation for competitive inhibitor binding.17 DHF was held constant at 100 µM for all 
IC50 determinations. The mock-purified E. coli SK037 expressing no hDHFR served as a 
negative control. 
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RESULTS AND DISCUSSION 
Selection of target residues for mutagenesis 
In silico visualization of active-site hDHFR residues known to interact with DHF 
and/or MTX was performed to identify residues for mutation. The crystal structure 
coordinates of the ternary complex of hDHFR with MTX and NADPH (1U72.pdb)7 and 
the binary complex of hDHFR with folic acid (1DHF.pdb)6 were visualized. Folate and 
MTX are constituted of a pteridine ring moiety, a p-aminobenzoyl group (p-ABA) and a 
L-glutamyl γ-carboxylate tail. The molecules are chemically and sterically similar. 
However, because of their differences, MTX binds to DHFR with its pteroyl moiety 
flipped 180° about the C6-C9 bond relative to folate (figure 3.1A and 3.1B). As a result, 
active-site residues form different contacts with the two molecules and binding of the 
inhibitor MTX is 2000-fold stronger than binding of the substrate DHF. 
MTX-resistant point mutants of DHFR from human or other mammalian sources 
have been identified either in vitro, in vivo or ex-vivo. Point mutations at residues 
Ile7,18,19 Gly15,20 Leu22,21,22 Trp24,19 Phe31,8,23  Phe34,24 Gln35,19 Arg7025 and Val11519 
have yielded DHFR variants with decreased MTX-affinity. In particular, saturation 
mutagenesis26 and in vitro characterization of mutants at residues 2221,22 and 318,23 have 
identified the specific mutations at these positions that confer MTX-resistance in vitro.  
Herein, we investigated five non-contiguous positions where no saturation 
mutagenesis had been performed previously: Ile7, Gly15, Trp24, Arg70 and Val115 
(figure 3.1C).  The backbone carbonyl groups of Ile7 and Val115 form hydrogen bonds 
with the 4-amino pteroyl group of bound MTX; these bonds are not formed with folate.7 
Trp24 and Arg70 are strictly invariant residues in all vertebrate and bacterial DHFRs. 
The indole nitrogen of Trp24 is hydrogen-bonded to the C4-oxygen of folate (N8 of 
MTX) via a conserved water molecule. Arg70 makes ionic interactions with the α-
carboxylate of the L-glutamate moiety of both folate and MTX. The mutation R70K 
weakens binding to both ligands.25 Gly15, also selected for mutagenesis, is a highly 
conserved residue located on a loop outside the active site (figure 3.1C). It has no known 
interaction, direct or indirect, with NADPH, DHF or MTX. Nonetheless, mutant G15W 
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was isolated in vivo from a MTX-resistant subline of murine leukemic cells implanted in 
mice,27 justifying further investigation.  
Mutagenesis and expression 
Saturation mutagenesis was performed to obtain individual libraries encoding the 
20 amino acids at positions 7, 15, 24, 70 and 115 of hDHFR (libraries 7, 15, 24, 70 and 
115, respectively). The libraries were subcloned into pQE32 to provide His6-tagged 
variants for ease of purification. The His6-tag causes no detectable variation in WT 
hDHFR kinetic parameters.8 The libraries were transformed into E. coli SK037, a MTX-
sensitive strain that is a knock-out of the tolC component of a multi-drug-resistance 
(MDR) efflux pump.13 Approximately 1 × 104 colonies were obtained per library. DNA 
sequencing of randomly chosen clones propagated on non-selective medium revealed 
little or no sequence biases and no non-specific mutations. For library 115, DNA 
sequencing of 42 clones selected for activity and 46 nonselected clones allowed 
identification of 18 out of the 20 possible variants (mutants V115D and V115E were not 
identified). 
Selection and screening for catalytically active mutants 
The 2-tier selection strategy to identify catalytically active mutants is depicted in 
figure 3.2A. To verify whether the 2-tier strategy could reliably select active variants, we 
validated it against library 115. This library had shown a range of activity levels upon 
preliminary screening and was judged a good candidate to assess sensitivity and 
prevalence of false positives or false negatives. The 1st-tier assay is a bacterial 
complementation assay allowing high-throughput selection of active variants. For this 
assay, the library was plated on selective MM_AT medium containing trimethoprim 
(TMP). TMP inhibits the endogenous bacterial DHFR, making bacterial propagation on 
minimal medium obligatorily dependent on the activity of the expressed variant of 
hDHFR. E. coli SK037 transformed with pQE2 or with WT hDHFR-pQE32 was used as 
negative and positive controls, respectively. No bacterial growth was observed for the 
negative control whereas a survival rate varying between 88% and 100% was observed 
for the positive control. DNA sequencing of 42 selected colonies yielded 8 unique 
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hDHFR variants (7 mutants and the WT) (figure 3.3A). The WT (Val115) was the most 
frequently selected variant (48%), followed by V115I (32%), V115M (10%) and V115C, 
V115L, V115F, V115Y and V115A (2% each) (figure 3.4A).  We observed no bias 
resulting from the distribution of the 32 codons of the ‘NNS’ approach to saturation 
mutagenesis. Thus, the NNS codon encodes the WT Val at a frequency of 2/32, the 
V115I, M, C, F and Y at a frequency of 1/32 and the V115L at a frequency of 3/32; 
nonselected mutations are also encoded at frequencies varying between 1/32 and 3/32. 
Not all variants identified as active by bacterial complementation were necessarily 
suitable for in vitro characterization. If the threshold for significant activity is higher in 
vitro than in vivo, some variants that allow cellular propagation may appear to be inactive 
in vitro and would thus constitute false positive hits from bacterial selection. Factors such 
as expression level, solubility and stability may have differing effects in vivo and in vitro. 
Moreover, if a greater number of selected colonies had been sequenced, further active 
variants at position 115 may have been identified. Failure to identify these would result in 
false negatives from bacterial selection.  
To evaluate prevalence of false negatives, both the active, selected variants as 
well as the active but non-selected variants (14 variants in total, see figure 3.4) were 
individually plated under the bacterial selective conditions. All variants identified in the 
1st-tier selection step conferred high survival rates while all others resulted in negligible 
or no survival (figure 3.4A). Thus, bacterial selection of library 115 gave no false 
negatives. 
To evaluate prevalence of false-positive hits in the 1st-tier selection, the 2nd-tier 
96-well plate-based screening assay was applied to library 115 variants. Despite having 
lower throughput than the selection step, it has the advantage of rapidly providing an 
estimate of the kinetic constant kcat. To assess activity independently of bacterial 
selection, the selected variants as well as the nonselected variants were subjected to the in 
vitro activity assay (18 variants). DHFR activity was assayed directly from cell lysates in 
96-well plate-based assays. When available, at least 2 clones were assayed per mutant. 
No significant differences in reaction rates were observed in absence or presence of TMP. 
This indicates that there is no significant background due to endogenous bacterial DHFR. 
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E. coli SK037 transformed with pQE2 also served as a negative control. Again, the 
bacterial DHFR gave a negligible signal relative to the overexpressed hDHFR variants. 
The WT was always identified as being active both in bacterial selection and in vitro, 
which was an essential validation of the reliability of the method. 
 Clones with > 2-fold the in vitro activity of the negative control pQE2/SK037 
were considered active. This threshold was established on the basis of the reproducibly 
weak signal obtained for the negative controls (at least 2 negative controls were included 
on each 96-well plate) as well as the sensitivity of plate-reader. Because the assay was 
performed with crude lysate rather than purified enzyme, any active but poorly expressed, 
poorly soluble or unstable mutant would be classified as inactive if the overall activity 
were < 2-fold pQE2/SK037. All library 115 variants that were identified in the first-tier 
bacterial selection were also active in vitro, confirming that the selection yielded no false 
positive hits (figure 3.3A and 3.4B). The kcat for all active variants from library 115 
roughly correlated with the frequency of occurrence of the mutants during bacterial 
selection (figure 3.4B and table 3.1). When more than 1 clone was assayed for a given 
mutation, the data were generally in agreement. However, mutants V115T, V115Q, 
V115N, V115S, V115K and V115G, which had not been selected in vivo and which 
yielded no significant cellular propagation when individually plated (figure 3.4A), were 
also identified as active in vitro. The most active mutant, V115T, exhibited a native-like 
kcat. While these mutants possessed readily assayed activity, their overall properties 
(potentially including KM changes) did not provide sufficient turnover to support bacterial 
growth. These variants were not false negatives according to the criteria required for 
bacterial propagation, which is the ultimate goal of our work. Nonetheless, they illustrate 
that there can be a loss of underlying structure-activity information if only the bacterial-
selected variants are subjected to the 2nd-tier assay for in vitro activity, as this assay can 
reveal individual properties of specific interest.  
Having validated the reliability of the 2-tier selection procedure, it was applied to 
the remaining libraries. Following 1st-tier selection for activity, 16 selected clones per 
library were subjected to DNA sequencing analysis, allowing identification of mutations 
compatible with cell survival (figure 3.3A). Survival rates for the different libraries 
varied between 3% and 7% and a variety of mutations were tolerated at each targeted 
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position. The mutants conferring survival were then tested in vitro in the 2nd-tier assay, 
allowing for identification of stable, soluble and active mutants (figure 3.3A). For 
libraries 7 and 24, most of the bacterial-selected mutants were active in vitro, with 
elimination of at most 1 false positive hit per library. Five false-positive mutants were 
eliminated from each of library 15 and 70. In library 70 only the native Arg showed 
detectable activity in vitro. Contrary to the results of library 115, where no false-positives 
were identified, not all mutants obtained in the 1st-tier selection showed significant in 
vitro activity. The correlation between in vivo and in vitro activity appears to depend on 
the particular library and on the threshold chosen to define activity, where mutations at 
the different positions have differing effects on the overall properties of the enzyme. 
Mutations that support catalytic activity 
Position 115 tolerated the greatest number of mutations. The active variant V115P 
was previously reported in the highly homologous mouse DHFR (mDHFR) but was 
unstable,27 and its hDHFR counterpart was incompatible with bacterial propagation in 
this study. Positions 7 and 15 tolerated only a restricted subset of conservative mutations. 
Gly15, located farther from the active site than the other targeted residues, tolerated the 
conservative mutation G15A. The only reported mutation of hDHFR at position 15, 
G15W, was described as active but unstable.20 This is consistent with it having been 
identified in the 1st-tier bacterial selection but eliminated in the 2nd-tier in vitro assay.  
Position 7 tolerated only the conservative mutations I7L and I7V. As in the case of 
Val115, the main-chain carbonyl of Ile7 is hydrogen-bonded to MTX but not to DHF.7 
The only active hDHFR mutation previously described at position 7 was I7F.18 This 
mutant was identified in the 1st-tier bacterial selection but was rejected in the in vitro 
assay, its activity being slightly inferior to the chosen threshold. Considering that its 
expression level and solubility were comparable to the WT (data not shown), its low in 
vitro activity is likely a result of its reported instability and its high KMDHF.18 Because its 
activity in vitro was not negligible, we determined its kinetic parameters using purified 
enzyme (kcat = 2.1 ± 0.1 s-1, KMDHF = 14.9 ± 3.6 μM; kcat/KMDHF = 0.16 μM-1s-1), 
confirming the reported data (kcat = 5.0 ± 0.2 s-1, KMDHF = 20 ± 2.1 μM; kcat/KMDHF = 0.25 
μM-1s-1).18  The exclusion of this variant following the in vitro assay does not point to 
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disagreement with previous studies but highlights the advantage of comparing all variants 
on the basis of a user-defined threshold for a specific parameter, where only variants 
surpassing that value are considered to be sufficiently fit for a given application.   
Residues Trp24 and Arg70 are highly conserved in various species and are known 
to be important for DHF binding.25,28 Moreover, Arg70 appears to be involved in 
maintaining the structure of the binding site.25 Position 70 tolerated no substitution that 
allowed significant in vitro catalytic activity. The conservative hDHFR mutation R70K 
has been previously described (kcat = 1.75 s-1, KMDHF = 0.47 μM; kcat/KMDHF = 3.7 μM-1s-1 
at pH 7.5).25 Its stability was comparable to the WT.25 The mutation R70K was identified 
in the 1st-tier bacterial selection, but was then eliminated in the following step (figure 
3.3A; 2 independent clones tested). Factors such as lower expression level or solubility 
may have contributed to reduce its in vitro fitness below the established threshold. 
Position 24 tolerated the conservative substitutions W24F and W24Y (figure 3.3A). The 
hDHFR mutation W24F was previously described as being compatible with activity 
(KMDHF increased 25-fold and a 3-fold increase in kcat relative to WT) but its stability was 
3-fold lower than the WT.  NADPH binding was also weakened and the rate of hydride 
transfer was markedly decreased, illustrating its importance for substrate binding and 
catalysis;28 nonetheless, its resulting activity was above the threshold. Mutation W24R in 
mDHFR was reported to be very poorly active,19 and was not tolerated by hDHFR in this 
study (figure 3.3A). 
Overall, the parallel comparison of a large number of mutations of a human gene 
by the rapid means of bacterial propagation was shown to provide a reliable indicator of 
global activity. Further sorting by the 2nd-tier in vitro assay allowed efficient retention of 
the variants that best met the user-specified parameters. The selected variants were 
overwhelmingly in agreement with published data and readily allowed identification of 
novel, active point mutants of hDHFR.  
Selection and screening for MTX resistance 
In parallel with the activity assay, a 2-tier selection strategy was developed to 
identify MTX-resistant hDHFR mutants (figure 3.2B). In the 1st-tier bacterial selection 
step, the 5 libraries were selected on medium containing 1 mM MTX (ATM-1000). MTX 
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inhibits the hDHFR variants that are not resistant, making the survival of bacteria on 
minimal medium dependent on the activity of the hDHFR variants that are active as well 
as MTX-resistant. It should be noted that, despite the increased MTX sensitivity of E. 
coli SK037, it exhibited relatively high intrinsic MTX resistance such that > 200 μM 
MTX was required for efficient bacterial selection. No bacterial growth was observed for 
the negative control expressing only endogenous bacterial DHFR. When the WT hDHFR 
was expressed, very low survival was observed (0.002%), consistent with its sensitivity 
to MTX. Survival of all libraries was low (≤ 0.03%), suggesting that few MTX-resistant 
variants were present and highlighting the importance of verifying the occurrence of 
false-positives. DNA sequencing following selection allowed identification of 2 to 6 
mutations at each targeted position (figure 3.3B).  
The 2nd-tier screening step using the 96-well plate screening assay was used to 
eliminate false positives. The clones identified as being MTX-resistant by bacterial 
selection were assayed for residual activity in the presence of 200 nM MTX (table 3.1) or 
1000 nM MTX (not shown), relative to activity in the absence of MTX. These 2 
concentrations were selected based on IC50MTX (estimated at 100 μM DHF) for 
previously-characterized, MTX-resistant point mutants: L22Y (IC50MTX ≅ 2000 nM, 
where KMDHF = 0.53 µM and KiMTX = 10.9 nM);22 L22W (IC50MTX ≅ 1000 nM, where 
KMDHF = 0.42 μM and KiMTX = 4.31 nM);22 L22R (IC50MTX ≅ 290 nM, where KMDHF = 1.6 
and KiMTX = 4.57)22 as well as I7F (IC50MTX ≅ 272 ± 72 nM, this study). The assays were 
conducted using the same cell-lysate dilutions as for the activity test. Cell lysate from 
SK037 expressing no hDHFR or expressing WT hDHFR-pQE32 were used as negative 
controls for MTX-resistance. Previously characterized hDHFR mutants displaying a 
broad range of MTX-resistance levels were used as positive controls: mutant 
F31A/F34V/Q35H (AVH; KiMTX= 180 nM), mutant F31R/F34T/Q35R (RTR; KiMTX= 86 
nM) and point-mutant F31P (KiMTX= 1.7 nM).8 Mutants AVH and RTR showed residual 
activity higher than 40% at both concentrations of MTX tested, consistent with their high 
IC50MTX under these conditions (4400 nM and 3500 nM, respectively). F31P showed a 
residual activity > 40% at 200 nM MTX but not at 1000 nM, consistent with its IC50MTX 
under these conditions (110 nM). On the basis of these observations, a threshold of 
  
104
residual activity > 40% at 200 nM MTX was established as being minimally required to 
consider a mutant as MTX-resistant.  
Two mutants from library 115 (V115A and V115C) were effectively resistant to 
MTX on the basis of the threshold (figure 3.3B and table 3.1). These had never been 
previously reported. Other mutants had residual activities higher than WT hDHFR but 
were rejected because these values were below the established threshold. Previously 
reported MTX-resistant mutants of hDHFR I7F18 and R70K25 were identified at the 1st-
tier level but rejected at the 2nd-tier screening as their overall activity in vitro did not 
meet the required criteria, as discussed above. Despite the fact that the purified I7F 
mutant was effectively MTX-resistant, with a KiMTX = 31.9 ± 8.5 nM ( > 1000-fold 
increase relative to WT), the > 200-fold increase in KMDHF 18 and/or further modified 
properties contributed to decrease in vitro activity below the established threshold. G15W 
has also been reported as being MTX-resistant but unstable;20 its fitness was too low even 
to allow 1st-tier selection for resistance. 
As a further control for robustness of the strategy, the mutants encoded in library 
115 (18 variants) were all individually tested for residual activity at 200 and 1000 nM 
MTX. The only mutants with a residual activity > 40% in presence of 200 nM MTX were 
V115A and V115C. Thus, the bacterial selection for MTX-resistance yielded no false 
negatives in library 115.  
The IC50MTX values for all library 115 mutants that showed non-negligible in vitro 
activity were measured in 96-well plates directly from cell lysates (table 3.1 and figure 
3.5A). This assay was less rapid but more precise than the simple assay of residual 
activity. Only mutants V115A and V115C presented an IC50MTX higher than 200 nM. 
Other mutants (e.g V115L, V115K, V115T and V115G) had an IC50MTX higher than the 
WT hDHFR but lower than the established threshold of resistance (200 nM MTX). These 
results confirm the validity of relying on the simple indicator of residual activity to 
reliably identify MTX resistance. Thus, the rapid 2-step protocol consisting of bacterial 
selection followed by in vitro measurement of residual activity provided sufficient 
information to identify hDHFR variants satisfying our specific requirements for 
resistance. 
  
105
Screening for modified binding to additional antifolate compounds 
To verify the flexibility of the method, it was applied to testing against the 
antifolate TMP. Because human DHFR is intrinsically resistant to TMP (KiTMP WT 
hDHFR = 960 ± 30 nM relative to KiTMP WT E. coli DHFR = 0.08 nM)29, we screened for 
increased sensitivity rather than resistance. The 1st-tier bacterial selection step cannot be 
applied to this compound because the endogenous bacterial DHFR will confer bacterial 
growth in absence of TMP. We performed the 2nd-tier in vitro reaction rate 
measurements for library 115 in absence or presence of 0.34 µM and 3.4 µM TMP. As 
mentioned previously, there was no significant background in vitro due to endogenous 
bacterial DHFR. In no case was a significant difference in reaction rates observed, 
indicating that no library 115 variants tested were rendered TMP-sensitive as a result of 
mutation. This confirmed that TMP sensitivity was not the cause of reduced cellular 
propagation in the bacterial selection presented above.  
Preliminary tests were performed to assess resistance to the clinically relevant 
antifolate pemetrexed (PMTX). Pemetrexed inhibits multiple folate-utilizing enzymes, 
including thymidylate synthase and hDHFR4. Because bacterial selection using 
pemetrexed could not be interpreted solely on the basis of hDHFR resistance, only the 
2nd-tier in vitro screen was performed. Active clones from the 5 libraries considered in 
this study were assayed in crude lysate for residual activity in the presence of 5 µM 
PMTX (table 3.1) or 20 µM (not shown) PMTX, relative to activity in the absence of 
PMTX. These concentrations were selected based on the value of IC50PMTX ≅ 0.75 ± 
0.3μM determined for the purified WT hDHFR. Using the same negative controls as for 
MTX-resistance, mutants with residual activity significantly greater than the WT residual 
activity at 5 µM PMTX were considered PMTX-resistant (table 3.1). Screening results 
suggest that, as for MTX, variants V115A and V115C may be PMTX-resistant. Variants 
V115L and V115I also showed potential PMTX resistance according to residual activity.   
Kinetic and inhibition parameters of the novel antifolate-resistant mutants 
The WT and the novel MTX and/or PMTX-resistant mutants (V115A and V115C, 
V115I, V115L) identified in the 2nd-tier screen were expressed, purified to 90-95% 
purity and characterized according to their kinetic and inhibition parameters (table 3.2). 
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Their expression levels were comparable, and as for WT hDHFR, mutants were 
approximately 50% soluble (data not shown). Catalytic efficiencies (kcat/KMDHF) for 
variants V115A and V115C were reduced by approximately 700 and 1400-fold, 
respectively, relative to WT. KMDHF for V115A and V115C was increased at least 100-
fold relative to WT while turnover (kcat) was reduced only 4 and 15-fold, respectively, 
relative to WT. The inhibition constants confirmed that both variants were effectively 
MTX-resistant, having KiMTX = 20 nM, which is > 600-fold higher than the WT and 
compares favorably to the well-characterized resistant point mutant L22Y (KiMTX = 10.9 
nM).22 It should be noted that IC50MTX for V115A and V115C from crude lysate or in 
purified form were comparable (table 3.1 and table 3.2; figure 3.5). This demonstrates 
the accuracy of the rapid determination of IC50MTX directly from cell lysate in the 96-well 
plate format. Variants V115A and V115C were also shown to be PMTX-resistant as their 
KiPMTX values were > 250-fold greater than the WT hDHFR.  
Variant V115L showed ~ 5-fold increase in IC50MTX relative to WT (table 3.1; 
table 3.2), which was below our user-defined threshold for resistance. Nonetheless, 
determination of its KiMTX confirmed that it confers MTX-resistance, albeit at a lower 
level than variants V115A and V115C (table 3.2). This variant showed the greatest 
increase in KiPMTX, with a > 700-fold increase relative to WT. Taken with the results for 
variant V115A, which shows high MTX resistance and moderate PMTX resistance, our 
results suggest that variants at position 115 may confer a differential degree of resistance 
to the specific antifolates tested, despite the structural similarity of the compounds. We 
are pursuing more detailed studies relative to this question. 
Variant V115I was not MTX resistant but was identified as being potentially 
PMTX resistant according to residual activity (table 3.1). However, further analysis 
demonstrated that it is not PMTX resistant and thus constitutes a false-positive hit from 
the second-tier residual activity screen. 
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CONCLUSIONS 
An efficient 2-tier selection strategy was applied to the selection of active and 
MTX-resistant hDHFR variants from 5 hDHFR libraries created by saturation 
mutagenesis of active-site residues. This allowed, for the 1st time, exhaustive screening 
and identification of mutations compatible with hDHFR activity at these positions. The 2 
tiers showed reliability and complementarity with respect to identification of active 
hDHFR variants. The 1st-tier bacterial selection results of library 115 confirmed that the 
most frequently selected variants conferred better survival rates. All selected mutants 
from library 115 were also active in the 2nd tier, in vitro assay. Because the 2nd-tier 
assay has user-defined parameters, varying the threshold for activity or the assay 
conditions (substrate and cofactor concentrations) will yield additional information 
relative to the effect of mutations on catalytic activity. In general, where active, stable 
and soluble variants have been reported, they were selected in the 2nd-tier activity assay, 
further validating the selection strategy. Thus, the bacterial selection for activity was 
shown to be robust and the in vitro screening allowed rapid preliminary kinetic 
characterization of novel active hDHFR variants. 
The addition of MTX to the 2-tier procedure allowed identification of MTX-
resistant point mutants at these positions, among which 2 are novel variants. There was 
no evidence of false-negatives upon bacterial selection. False-positives were readily 
eliminated upon in vitro screening, for which the IC50MTX values obtained from crude 
lysate were comparable to those obtained with purified enzyme. The concentrations of 
MTX for tests of residual growth were set by the operator and determined the extent of 
resistance that was sought. In this work, the concentrations of MTX were selected 
according to properties of previously-characterized point mutants, since our aim was to 
match or surpass that level of resistance. By increasing the threshold, only the most 
highly resistant mutants would be identified.  
The method described is ideal for screening large libraries, the 1st-tier bacterial 
selection being high-throughput and the 2nd-tier assay allowing rapid detection of the 
best variants among the leads, according to user-defined parameters. The approach has 
proven efficient in rapidly assessing key kinetic parameters in enzyme variants. Simple 
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modification of the protocol readily allowed screening against further compounds; 
preliminary screening has allowed identification of three novel pemetrexed-resistant 
variants by this approach. The 2-tier strategy should also prove adaptable to screening 
other metabolically-essential enzymes that can complement a bacterial strain rendered 
metabolically deficient via chemical or genetic methods, and where a colorimetric or 
fluorogenic assay can reliably report activity in crude bacterial lysate.  
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Table 3.1. Reactivity (kcat) and MTX or PMTX resistance determined in 96-well 
plates using crude lysates of active hDHFR variants from library 115. 
Library 115 
variants a 
kcat relative to 
WT 
Residual activity (%) 
at 200 nM MTX b 
IC50MTX 
(nM) c 
Residual activity (%) 
at 5 μM PMTX d 
V (WT) 1 11 20 ± 12 30 
I 5.0 8 0.4 ± 0.3 49 
M 0.68 12 19 ± 4 11 
C  0.27 67 400 ± 69 51 
L 0.45 30 130 ± 25 80 
A 0.27 49 220 ± 17 50 
F 0.23 –  e 47 ± 41 –   
Y 0.29 18 38 ± 8 16 
T 0.94 35 76 ± 13 30 
S 0.35 24 76 ± 7 22 
K 0.33 34 96 ± 18 28 
G 0.21 30 67 ± 5 30 
Q 0.024 –   27 ± 7 –   
N 0.020 –   51 ±18 –   
 
Variants are grouped according to frequency of bacterial selection for activity (figure 3.4). 
a IC50MTX could be calculated only where a non-negligible kcat was recorded. 
b Variants in bold-type were considered MTX-resistant according to the user-defined threshold of 
residual activity at 200 nM MTX being greater than 40%, as defined under Results. 
c Mean ± SD; n = 3. Variants in bold-type were considered MTX-resistant according to the user-
defined threshold of IC50MTX ≥ 200 nM, as defined under Results. 
d Variants in bold-type were considered PMTX-resistant according to the user-defined threshold 
of residual activity at 5 µM PMTX being significantly greater than the WT residual activity. 
e ‘-’ indicates that activity was not detectable. 
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Table 3.2. Kinetic and inhibition constants a of purified MTX or PMTX-resistant hDHFR mutants.  
hDHFR 
variant  
kcat (s
-1)  KM
DHF(μM) 
kcat/KMDHF 
 (μM-1 s-1) 
IC50MTX (nM) KiMTX  (nM) 
IC50PMTX 
(μM) 
KiPMTX  
(nM) 
Wild-type  10 ± 2.0 < 0.075 > 138 41 ± 14 < 0.031 0.75 ± 0.3 < 0.5 
V115C 0.65 ± 0.02 7 ± 1 0.1 330 ± 29 20 ± 4 4.3 ± 1.6 283 ± 44 
V115A 2.8 ± 0.2 15 ± 2 0.2 150 ± 18 20 ± 5 1 ± 0.3 131 ± 87 
V115L ND b 4 ± 0.5 ND 190 ± 60 7.3 ± 2.7 9 ± 4 378 ± 118 
V115I 1.3 ± 0.05 < 1 > 1.3 20 ± 8 < 0.2 0.2 ± 0.03 < 2 
 
a Mean ± SD; n = 3 except for mutant V115L where n = 2. 
b ND: not determined 
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Figure 3.1. (A) Structures of folate (1DRF.pdb) and MTX (1U72.pdb) bound to hDHFR 
active site, with atom numbering. (B) The active-site area of hDHFR with bound MTX 
(1U72.pdb), illustrating the residues targeted for saturation mutagenesis (yellow sticks) as 
well as residues mutated in a previous study8 (white sticks). 
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Figure 3.2. Flow-chart of the two-tier strategy to select mutated hDHFR library 
variants for A) catalytic activity or B) methotrexate (MTX) resistance. The first-tier 
selection relies on bacterial propagation in the presence of trimethoprim (TMP). Colonies 
are picked into 96-well plates for second-tier screening using crude bacterial lysate. 
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Figure 3.3. Comparison of hDHFR mutations that allow for conservation of activity 
(A) or MTX resistance (B) on the basis of the two-tier selection strategy. Residues 
subjected to mutagenesis are depicted relative to the WT hDHFR primary sequence. Above 
the sequence are the mutants identified in the first-tier bacterial selection. The size of the 
font is related to the frequency of occurrence in the selection: small (< 10 %), medium (10 
to 30%), large ( > 30%). Below the sequence are the mutations identified in the second-tier 
in vitro assay. Clones with (A) > 2-fold the in vitro activity of the negative control were 
considered active and clones with (B) residual activity > 40% at 200 nM MTX were 
considered MTX-resistant.  Mutations at each targeted position are grouped as follows: 
small, hydrophobic (first column); aromatic (second column); polar and charged (third 
column). The WT residue at each targeted position is shown in grey.  
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Figure 3.4. The two-tier selection results for library 115. (A) Comparison of the 
frequency of occurrence of mutations following bacterial library selection (black bars) and 
bacterial survival rates from plating individual variants (grey bars). Variants T, S, K, G, Q 
and N showed negligible selection rates (between 0.02 % and 0.002 %) while variants W, 
H, R and P were not selected (= 0). All variants showing in vitro activity (see Panel B) 
were individually plated. (B) Frequency of occurrence of mutations following bacterial 
library selection (black bars) and kcat relative to WT (Val115) for individual variants (grey 
bars). Variants D and E were not individually tested. 
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Figure 3.5. IC50MTX concentration-response curves (mean ± SD; n = 3) of WT hDHFR (■), 
V115A (●) and V115 C (▲) using (A) crude lysate or (B) purified enzyme. 
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Section 3.2 - Erratum corrigendum  
Kinetic investigation with a new inhibitor allowed identification of a mistake 
occurred during previous characterization of mutant hDHFR V115L. Corrected values for 
V115L are  
KMDHF < 0.1 μM,  
KiMTX < 0.048 nM 
KiPMTX < 2.3 nM 
The mistake was due to erroneous interpretation of the kinetic data due to a very low 
signal. The mutant was repurified from two different clones and characterized in 
triplicate. For the characterization of KMDHF 10-cm quartz cells were used to amplify the 
signal. 
As a consequence of the correction, V115L, like V115I, was found to be a false 
positive for MTX resistance. Substitution of Val115 with both the conservative residues 
Leu and Ile resulted in mutated variants with kinetic and inhibitory parameters 
comparable to those of the native enzyme. The kinetic and inhibition values for all the 
other mutants were confirmed. 
A corrigendum note to JBS is being prepared.  
  
120
Chapter 4 – Binding of fragments of MTX to hDHFR 
 
4.0 - Preface 
In order to better elucidate the determinants of ligand binding in the active site of 
hDHFR, we proposed to correlate the kinetic and inhibitory parameters of hDHFR 
mutants of interest to their structural properties. The kinetic and inhibitory 
characterization of the mutants indentified in this study was described in details in 
chapter 2 and 3. Here, a more detailed structure-function investigation of binding of MTX 
to hDHFR will be described. Productive binding (Ki) of MTX fragments to the native 
enzyme and to four highly MTX-resistant hDHFR mutants will be used as a parameter to 
evaluate how different parts of the inhibitor and different active-site residues contribute 
to the overall binding MTX to hDHFR. 
 
4.1 - Introduction  
Multiple interactions are generated within the enzyme around the ligand’s 
functional groups. These interactions determine selectivity, strength of binding and ligand 
orientation. Do fragments of a ligand bind in the same orientation as the entire molecule? 
If this is the case, a quantification of the relative contributions of individual portions of 
the ligand in binding may offer considerable insight into the principles of drug 
recognition [103, 113, 114]. 
We investigated the relative importance of different parts of the inhibitor MTX in binding 
to the human DHFR by determining their inhibition constants (Ki) for the WT enzyme. 
Moreover, we have begun investigating the relative importance of residues located in 
different areas of the active-site by performing binding studies with these fragments 
towards mutant hDHFRs. The three different MTX fragments considered are illustrated 
in figure 1.7. DAP (2,4-diamino-6-(hydroxymethyl)pteridine) represents the pteridine 
moiety of MTX; DAMPA (4-[N-(2,4-diamino-6-pteridinylmethyl)-N-methylamino] 
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benzoic acid) the N10-methyl p-ABA pteroyl portion; p-ABA-Glu (N-(4-aminobenzoyl)-
L-glutamic acid) the p-ABA-Glu portion.  
Binding studies with MTX fragments DAP and p-ABA-Glu were previously 
reported for the DHFR from Lactobacillus casei [115-117]. On the basis of NMR 
evidence [115] supporting the hypothesis that both DAP and p-ABA-L-Glu bind to the 
enzyme similarly to MTX, Birdsall et al. determined the KD for both DAP (1.28 mM) and 
p-ABA-L-Glu (0.83 mM) and for N-methyl-p-ABA-L-glutamate, which is a fragment 
more similar to MTX than p-ABA-L-Glu (1.05 mM) [117]. Thus, binding of all 
fragments was much weaker than binding of MTX (KDMTX = 2 pM) [117, 118].  
Preliminary results with DAP and p-ABA-Glu were performed in our group by 
summer student Vanessa Guerrero and PhD student Mirja Krause, respectively (data not 
shown). Their results confirmed that DAP is a weak inhibitor also of hDHFR (IC50DAMPA 
for WT hDHFR was 16000-fold lower than IC50MTX, both measured using 100 μM DHF 
in the assay) while p-ABA-Glu does not inhibit hDHFR. Therefore, both DAP and p-
ABA-Glu were not suitable for our purposes and were abandoned.  
Preliminary results for binding of DAMPA to native hDHFR and mutants 
F31R/Q35E (RFE), F31R, Q35E and V115A will be presented and discussed in the 
following paragraphs. 
 
4.2 - Materials and methods 
4.2.1 Reagents and enzymes 
DAMPA was purchased from Sigma. All other reagents were purchased or 
prepared as described in chapters 2 and 3. F31R/Q35E hDHFR and V115A were 
identified as highly MTX-resistant mutants and are described in chapters 2 and 3, 
respectively. Mutants F31R and Q35E were created by site-directed mutagenesis by PhD 
student Jordan Volpato. 
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4.2.2 Determination of binding parameters 
Enzyme expression and purification, DHF and NADPH quantification and rate 
measurements were performed as previously described in both chapters 2 and 3. DAMPA 
was dissolved in 0.1 N NaOH and quantified by spectrophotometry (ε370nm = 6568 M-1cm-
1).   IC50DAMPA were determined in 1-cm cells in the presence of 100 μM of both DHF and 
NADPH and different concentrations of DAMPA: 0, 0.1, 0.5, 1, 5, 10, 50, 200 μM for 
WT and Q35E; 0, 1, 5, 10, 50, 100, 200, 500, 1000 μM for RFE and F31R. KiDAMPA was 
calculated from IC50DAMPA assuming the mode of binding was competitive. IC50MTX for 
both F31R and Q35E was determined by summer student Vanessa Guerrero using  100, 
350, 800, 1600, 3200, 6400 and 15000  μM and 0, 0.025, 0.05, 0.1,0.5, 1 and 10 μM of 
MTX, respectively. KiMTX  for mutants F31R and Q35E were calculated according to the 
equation for competitive inhibitor binding. ΔΔG (kcal mol-1) values were calculated from 
experimental Ki values using the following equation: 
ΔΔG = -RT ln (Kimut/KiWT)           
R is the molar gas constant and T is the temperature in Kelvin. 
 
4.3 Results and discussion 
Mutants F31R/Q35E (RFE) and V115A were chosen as candidates for this 
preliminary study because they are located in different areas of the active site (therefore 
interact with different parts of the inhibitor) and they both confer high resistance to MTX. 
Mutants F31R and Q35E were created and characterized to evaluate the effect of the two 
individual mutations of RFE on binding of both MTX and DAMPA.  
Results are presented in table 4.1. MTX and its fragment DAMPA differ in that DAMPA 
has no glutamate tail (figure 1.7). The ratio KiDAMPA/KiMTX was used to describe the effect 
on binding of the glutamate tail, assuming that DAMPA binds similarly to MTX. The 
thermodynamic contribution to inhibition (ΔΔG) is used as quantitative parameter of 
binding. Kinetic characterization of KMDHF and Vmax in presence of different 
concentrations of DAMPA remains to be performed to determine if this compound is 
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effectively a competitive inhibitor of hDHFR. However, only structural data will confirm 
the precise orientation of the inhibitor in the enzyme’s binding site.  
DAMPA binds very tightly to WT hDHFR (Ki < 2 nM). This result suggests that 
the binding is highly specific and likely to be structurally very similar to MTX binding. 
KiDAMPA/KiMTX for the native enzyme shows that the lack of the glutamate tail accounts for 
a 60-fold decrease in binding.  
Mutation of residue 115 to Ala decreased binding of MTX and its fragments but, 
surprisingly, the effect on DAMPA was stronger than the effect on MTX. KiDAMPA/KiMTX  
V115A was 3-fold higher than for the WT. Since residue 115 is located far away from the 
glutamate portion of bound MTX (figure 1.5B), this suggests that distal effects are 
involved in binding the glutamate tail. Since distal effects cannot be detected from 
structural visualization, this result highlights the advantages of the presented approach to 
gain detailed information about binding. 
To evaluate both the contribution of a given mutation taken alone and its contribution in a 
combinatorial context, we built a double mutant cycle for the F31R/Q35E hDHFR 
variant. Table 4.1 and figure 4.1A illustrate that combination of point mutations F31R 
and Q35E in the double mutant F31R/Q35E enhances MTX- and DAMPA-resistance in a 
synergistic fashion, the major contribution resulting from point mutant F31R. Mutation 
Q35E slightly decreases the MTX binding and slightly increases the DAMPA binding. It 
is known that when the inhibitor does not occupy the active site, a sub-domain shift 
brings R70 into contact with Q35 [46]. When DAMPA is bound, it is possible that the 
insertion of a negative charge at position 35 (E35) favours its interaction with R70. In the 
case of MTX, putative repulsive forces between the glutamate tail of the inhibitor and 
E35 may be responsible for the slight increase in KiMTX.  
The ratio KiDAMPA/KiMTX is similar for the WT and for mutant F31R/Q35E. 
However, KiDAMPA/KiMTX ratios are very different for the point mutants and reflect an 
unpredictable synergistic contribution to the binding in the double mutant (table 4.1 and 
figure 4.1B).  
In conclusion, these preliminary results represent a proof of principle for the 
validity of using the MTX fragment DAMPA to gain further insights on the MTX 
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binding. Kinetic characterization of further mutants of interest, determination of the mode 
of binding by a kinetic approach and structural characterization by X-ray crystallography 
with DAMPA will be performed.  
125 
 
Table 4.1. Inhibition constantsa of MTX and DAMPA for WT and selected MTX-resistant hDHFR mutants.  
 MTX DAMPA 
 hDHFR variant 
Ki MTX  (nM) 
ΔΔG 
 MTX 
(kcal mol-1) 
Ki DAMPA  
(nM) 
ΔΔG 
DAMPA 
(kcal mol-1) 
KiDAMPA/ Ki MTX   
 WT < 0.031 - < 2  - > 65 
 V115A 20 ± 5 3.8 3500 ± 1200  4.38 175 (3×)b 
 F31R 1.12 ± 0.6 2.1 241 ± 50 2.81 215 (3×) 
 Q35E 0.048 0.26 0.45± 0.26 -0.87 10 (-6×) 
 F31R/Q35E (RFE) 21 ± 11 3.82 921 ± 164 3.59 45 (1×) 
a Mean ± SD; n=3 
b Values in parenthesis indicate the fold of difference relative to the value for the WT enzyme. Thus, they represent the combined effect of 
mutation in the enzyme and lack of the glutamate tail portion in the ligand. 
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Figure 4.1. Comparison of binding of MTX and its fragment DAMPA in the 
double mutant F31R/Q35E (RFE) and the corresponding single mutants F31R and 
Q35E. A) Inhibition constants (Ki) for MTX and DAMPA of hDHFR mutants F31R, 
Q35E and F31R/Q35E hDHFRs relative to WT. B) SAR (structure-activity relationship) 
presented as a double mutant cycle for ligand binding to F31R/Q35E. Each enzyme 
variant is in bold. Values in square brackets indicate the ratio KiDAMPA/KiMTX for each 
variant. DAMPA and MTX differ by the lack of the glutamate tail in DAMPA (figure 
1.7); thus the difference in binding of DAMPA and MTX reflects the contribution of the 
glutamate tail to binding. Values along the arrows represent the gain or loss in binding 
resulting both from mutation and from absence of the glutamate tail, determined from 
the ratio  KiDAMPA/KiMTX  for each mutant. Thus, the contribution of each mutation to the 
binding of each compound is revealed. 
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Chapter 5 – Docking for structure-function 
relationship analysis 
 
5.0 Preface 
Structural data are certainly a crucial element for structure-function relationship 
analysis, which is, ultimately, the main goal of this project. Our laboratory has an 
ongoing collaboration with the crystallography group of Prof. A. Berghuis at McGill 
University. The 1.7 Å-resolution structure of mutant F31R/Q35E complexed with MTX 
was recently obtained [119] and collaborative efforts to crystallize the variants 
presenting the greatest resistance in the presence of different relevant ligands are 
currently pursued. However, it is unrealistic to think of crystallizing and resolving the 
structure of many mutant-ligand complexes, because our experience has demonstrated 
that the mutated variants in the presence of various ligands do not readily yield high 
quality crystals. Therefore, it was necessary to identify an alternative, more efficient 
method to consider structural implication of mutations in ligand binding. Molecular 
modeling represents a solution to this problem. Among the modeling approaches 
available to us, we identified the method that best answered to our needs. While energy 
minimization (see chapter 2) is fast and can be informative when the orientation of the 
inhibitor in the binding site is known from structural data, it is not applicable to newer 
ligands for which this information is not available. In this section, the application of 
automated docking to predict ligand binding to the WT hDHFR will be described.  
 
5.1 Introduction  
Automated docking with Autodock 4 is a modeling approach to predict if and how 
small ligands bind to a target protein of known structure [120-122].  While simple 
energy minimization of mutant AVH complexed with MTX suggested reasonable 
insight into the structural causes of a reduced MTX binding (chapter 2) and proved to 
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be an informative approach for that study, we chose to test automated docking as a 
possible tool to predict binding of ligands for which no crystal structures in complex 
with hDHFR exists, such as DHF, PMTX and DAMPA. First, we validated the method 
by performing the docking with ligands for which DHFR-bound structure was available 
(FOL and MTX). Then, we used the same protocol to perform the docking of DHF and 
PMTX. The results of the PMTX binding were unexpected and highlighted the weak 
points of this methodology to perform structure-function analysis. 
 
5.2 Materials and Methods 
5.2.1 In silico automated docking of FOL, DHF, MTX and PMTX 
The starting coordinates were taken from the PDB file 1U72 of WT hDHFR 
complexed with the cofactor NADPH and the inhibitor MTX [22]. The crystallographic 
water molecules and the MTX coordinates were removed directly from the PDB file 
text. All substrates (FOL, DHF, MTX and PMTX) were prepared as PDB files using 
ChemDraw 8.0 and Chem3D 8.0 (CambridgeSoft Corporation). Energy minimization 
of ligands conformations was performed using the integrated MM2 energy 
minimization script of Chem3D.  
Automated docking runs were performed using the AutoDock 4 free software 
package (Scripps). Both the macromolecule (WT hDHFR complexed with NADPH) 
and the ligand were prepared as recommended by the Autodock protocol. AutoGrid was 
used to generate grid maps centered on the Cα of residue Phe34 and including the 
region that contained the entire folate-binding site and more than half of the NADPH-
binding site (grid point spacing of 0.375 Å). For each ligand tested, 50 docking runs 
were performed using the Lamarckian genetic algorithm [123] and using a starting 
population of 150 random ligand conformations. All other parameters were kept as 
suggested in the Autodock docking protocol. Seven torsions were allowed for each 
ligand (C6-C9, C9-C10, and the five torsions in the glutamate tail assigned by 
AutoTors) in order to allow rotable bonds to rotate. Following docking, clusters were 
evaluated according to the total binding energies calculated by AutoDock 4, and the 
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minimal energy conformation coming from the cluster at the lowest energy was 
retained for analysis. Ligand conformations in each cluster were also analyzed.  
5.3 Results and Discussion 
Docking of MTX and FOL were used to validate the approach, expecting the 
ligand orientation and the critical contacts with the hDHFR active-site residues to be 
similar to existing structural information. MTX binds in the active site with its pteridine 
moiety flipped 180° relative to folate (figure 1.6). Main interactions between the 
ligands (FOL and MTX) and hDHFR were described in chapter 1 and they are listed in 
table 1.1. The crystal structures used as a reference for comparison were 1U72.PDB 
(ternary WT hDHFR⋅NADPH⋅MTX complex)[22] and 1DHF.PDB (binary WT 
hDHFR⋅FOL complex)[18]. 
Autodock analysis is based on positional root mean square deviation (rmsd) of the 
corresponding atoms. The docked conformations are ranked in clusters in order of 
increasing energy. The autoDock’s analysis tool compares all docked conformations 
with one-another, and if two conformations have an rmsd between 0.5 Å and 2.0 Å 
(value set by the operator), they are both stored in the same cluster. Clusters are then 
ranked in order of increasing energy from the most negative to the most positive. The 
clustering results are indicated in table 5.1. In addition, conformations in table 5.1 are 
classified on the basis of the orientation of their pteroyl moiety.  
5.3.1 Docking of MTX 
The docking result with MTX showed the correct orientation of the ligand in the 
folate binding site and a good prediction of the interactions of MTX with the 
macromolecule (figure 5.1). The docked MTX (conformation of lowest binding 
energy) superimposed well with MTX from 1U72.PDB, the main difference being a 
significant shift of the glutamate γ-COOH towards N64, possibly driven by H-bonding 
interaction with the N64 side chain (figure 5.1). Despite this difference, the docking 
result was considered consistent with the interactions observed in the crystal structure. 
The cluster of lowest energy was constituted by 9 different conformations, 8 of 
which found the pterin 4-amino group oriented towards V115 (4-amino orientation), as 
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observed in the 1U72.PDB crystal structure, and 1 with its 4-amino group flipped (4-
oxo orientation), such as the pterin 4-carbonyl of FOL (1DHF.PDB)( table 5.1). Thus, 
the pteroyl orientation of the majority of docked conformations in the cluster of lowest 
energy correlated well with the structural data. 
5.3.2 Docking of FOL 
The FOL ligand was docked into 1U72.PDB, and not into 1DHF.PDB, because we 
wanted to evaluate the effects of the docking of a ligand to a structure other than the 
one from which it had been stripped out.   
Superimposition of the docked FOL (conformation of lowest binding energy), 
1U72.PDB and 1DHF.PDB (figure 5.2) showed that the orientation of the molecule 
was, as expected, similar to the one observed in 1DHF.PDB, with the 4-oxo group 
pointing in the opposite direction compared to the 4-amino group of MTX. A rotation 
and an upwards shift of the FOL pteridine ring relative to both FOL from 1DHF.PDB 
and MTX from 1U72.PDB was observed. This was possibly due to ring stacking 
interactions with the nicotinamide ring of NADPH, which is missing in the 1DHF.PDB 
crystal structure. Following the docking, interactions with residues F31 (not shown in 
figure 5.2), N64 and R70 of the enzyme were all maintained. Again, the result of the 
modeling was consistent with the observed structural data. 
Although the conformation of lowest energy was well oriented in the active site, 
the clustering results were poor. In fact, the cluster of the lowest energy was constituted 
by only 3 different conformations, 2 of which found the pterin 4-oxo group oriented 
towards W24 and E30 (4-oxo orientation), as observed in the crystal structure 
1DHF.PDB, and 1 with its 4-oxo group oriented towards V115 (4-amino orientation), 
like the pterin 4-amino group of MTX (table 5.1).  
5.3.3 Docking of DHF 
The instability of this compound, which is readily oxidized to folate, makes 
impossible to crystallize it within the folate-binding site, making the docking an 
interesting alternative to better understand the DHF binding. 
Following the docking, the orientation of the 4-carbonyl group of the conformation 
at lower energy was, as expected, the same as the FOL 4-oxo group. Most of the 
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docked conformations which entered the active site were in the expected 4-oxo 
orientation (table 5.1). However, the interactions with N64 and R70 were not 
preserved, due to a rotation of the p-ABA-Glu carbonyl and an inversion of α-COOH 
and γ-COOH of the glutamate tail (figure 5.3). The pteridine ring was positioned 
similarly to the pteridine ring of the docked FOL (result not shown in figure 5.3). 
Although it is likely that the p-ABA-Glu portion of bound FOL and DHF are oriented 
in the same way, important differences were observed following the docking, especially 
if we reason in the context of a SAR study.  
5.3.4 Docking of PMTX 
PMTX (figure 1.7) is a novel antifolate that inhibits the activity of human DHFR, 
as well as human thymidylate synthase (hTS) and to a lesser extent the purine 
biosynthesis enzymes GARFT and AICARFT [81]. PMTX contains a pyrrolo-
pyrimidine ring instead of the classical pterin ring and N10 is replaced by a carbon 
covalently bound to a non-polar methyl group. Like FOL, the double-ring moiety of 
PMTX contains a 2-amino and a 4-oxo group, in contrast to MTX, which contains 2,4-
diamino groups. Because of this difference, it has been suggested that PMTX binds the 
active site of hDHFR as FOL does, with the 4-oxo moiety pointing towards residues 
Glu30 and Trp24 [73]. This hypothesis is supported by the observation that 5-
deazafolate (figure 1.7), which is also a 4-oxo pteridine system and is structurally 
similar to both FOL and PMTX, binds in the same orientation as FOL [18]. Moreover, 
using molecular modeling, Gangjee A. et al. [73] suggested that PMTX binds to DHFR 
in the same orientation as FOL.  
Unexpectedly, the lowest energy conformation from the docking showed an 
orientation of the 6-5 ring-fused pyrrolo[2,3-d]pyrimidine moiety  similar to that of 
MTX, with the PMTX 4-carbonyl group and the MTX 4 –amino group pointing in the 
same direction (figure 5.4). Out of the 11 docked conformations in the cluster at lowest 
energy, 7 were in the 4-amino orientation and 4 in the 4-oxo orientation. Of the other 11 
conformations that docked into the FOL binding site, all bound in the 4-oxo mode 
(table 5.1). Unfortunately, due to the statistical representation of both orientations, it 
was impossible to make conlcusions on the binding mode of PMTX. The PMTX 
  
132
modeling study from Gangjee A. et al.[73] was performed using Sybyl 6.3, but the 
modeling approach they used and the results were not described, so we could not 
compare our results with theirs. 
  
5.4 Conclusion 
All ligands tested efficiently entered the folate binding-site and overall results for 
MTX and FOL docking were relatively accurate. The results with PMTX were in 
disagreement with the previous modeling results from Gangjee A. et al.[73], the 
conformation at lowest energy being in the 4-amino orientation. In the absence of a 
strong modeling evidence, structural data will be required to elucidate the binding 
orientation of PMTX. Our lab is currently working to obtain this information in 
collaboration with the group of Prof. A. Berghuis (McGill University). 
While automated docking is certainly a valuable tool to identify the inhibition 
potential of new molecules [124], it is also true that small differences can lead to 
erroneous interpretations when SAR (Structure-Activity Relationship) is the ultimate 
goal of the docking.  AutoDock 4 ranks ligand conformations in clusters by calculating 
binding energies on the basis of its scoring function [123]. Depending on the size of the 
ligand and the number of torsion angles allowed, it is possible to obtain a high number 
of clusters containing a small number of significantly different conformations. Docking 
can certainly be a useful tool for SAR when little structural information is available, but 
a careful analysis of clustering number, energies, and ligand conformations should be 
taken into account. Although we do not exclude the possibility of using AutoDock in 
the future for similar SAR applications, in the case of PMTX we prefer obtaining 
structural evidence before speculating on PMTX binding properties and effects of 
hDHFR mutations on binding. 
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Table 5.1. Docking clustering: orientation of the pteroyl ring in the active site 
 
Docked 
substrate 
Known or 
expected 
orientation 
Number 
of 
clustersa
Conformations 
in 4-oxo 
orientation 
Conformations 
in 4-amino 
orientation 
Conformations 
outside the active 
sited 
MTX 
 
 
 
 
4-amino 
orientation[22] 30 
1_6b; 2_1; 2_2; 
6_1; 6_2; 7_1; 
8_1; 9_1; 10_1; 
10_2 
1_1c-1_5; 
1_7-1_9; 
24_1 
 
3_1; 4_1-4_3; 5_1; 
11_1; 12_1; 13_1; 
14_1; 14_2; 15_1; 
15_2; 16_1; 
17_1-17_4; 
18_1; 19_1; 20_1; 
21_1; 21_2; 22_1; 
23_1; 25_1; 26_1; 
26_2; 27_1; 28_1; 
29_1; 30_1 
 
FOL 4-oxo orientation[18] 23 
1_1; 1_3; 4_1; 
12_1; 14_1 1_2; 2_1; 2_2 
3_1-3_4; 5_1-5_5; 
6_1; 6_2; 7_1; 
8_1-8_5; 9_1; 9_2; 
10_1; 11_1-11_4; 
13_1; 13_2; 14_2; 
15_1; 16_1; 16_2; 
17_1; 18_1-18_4; 
19_1; 19_2; 20_1; 
20_2; 21_1; 22_1; 
23_1 
DHF 4-oxo orientation 25 
1_1-1_7; 
2_1-2_4; 7_1; 
18_1 
19_1 
3_1-3_4; 4_1-4_6; 
5_1; 5_2; 6_1; 
8_1-8_3; 9_1-9_3; 
10_1; 11_1-11_4; 
12_1; 13_1; 14_1; 
15_1; 16_1; 17_1; 
20_1; 21_1; 22_1; 
23_1; 24_1; 25_1 
PMTX 4-oxo orientation 12 
1_5; 1_8-1_10; 
3_1; 3_2; 
4_1-4_6; 
5_1-5_3 
1_1-1_7; 
1_11 
 
2_1-2_6; 6_1; 
7_1-7_7; 8_1-8_6; 
9_1-9_4; 10_1; 11_1; 
11_2; 12_1 
a  Cluster: group of docked conformations with rmsd between 0.5 Å and 2.0 Å.   
b 1_6: docked conformations are indicated on the base of the cluster they belong (number in bold) 
and their ranking energy within the cluster (number in normal style). 
c docked conformation of lowest energy is underlined.   
d docked conformations that docked outside the folate binding pocket. 
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Figure 5.1. Docking of MTX into WT hDHFR⋅NADPH. Superimposition of 
docking result (MTX conformation of lowest binding energy) and 1U72.PDB (ternary 
complex WT hDHFR⋅NADPH⋅MTX). Docked MTX is in yellow. MTX from 
1U72.PDB is in magenta. Active-site residues I7, V115, Y121, R70 and N64 from 
1U72.PDB are highlighted as reference points. The 4-amino of docked MTX is circled 
in red. The γ-COOH of the glutamate tail of MTX is circled in black.  
 
 
 
  
135
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2. Docking of FOL into WT hDHFR⋅NADPH. Superimposition of docking 
result (FOL conformation of lowest binding energy), 1U72.PDB (ternary complex WT 
hDHFR⋅NADPH⋅MTX) and 1DHF.PDB (binary complex WT hDHFR⋅FOL). Active-
site residues I7, V115, Y121, R70 and N64 and the NADPH nicotinamide ring from 
1U72.PDB are highlighted.  The 4-oxo group of docked FOL is circled in red. A) 
Docked FOL is in yellow and FOL from 1DHF.PDB is in green. B) Docked FOL is in 
yellow and MTX from 1U72.PDB in magenta.  
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Figure 5.3. Docking of DHF into WT hDHFR⋅NADPH. Superimposition of docked 
DHF (conformation of lowest binding energy), 1U72.PDB (ternary complex WT 
hDHFR⋅NADPH⋅MTX) and 1DHF.PDB (binary complex WT hDHFR⋅FOL). Active-
site residues V115, R70 and N64 and the NADPH nicotinamide ring from 1U72.PDB 
are shown as reference points. Docked DHF is in yellow. FOL from 1DHF.PDB is in 
green. The 4-oxo group of docked DHF is circled in red. 
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Figure 5.4. Docking of PMTX into WT hDHFR⋅NADPH. Superimposition of 
docked PMTX (conformation of lowest binding energy) and 1U72.PDB (ternary 
complex WT hDHFR⋅NADPH⋅MTX). Active-site residues I7, V115, Y121, R70 and 
N64 and the NADPH nicotinamide ring from 1U72.PDB are shown. Docked PMTX is 
in yellow. MTX from 1U72.PDB is in magenta. The 4-carbonyl group of docked 
PMTX is circled in red. 
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Chapter 6 – Conclusions and perspectives 
 
In order to better understand the determinants of ligand binding, we applied 
directed evolution to the human DHFR, a well-characterized and clinically relevant 
enzyme which is an important target for the treatment of human proliferative diseases. A 
combined approach based on kinetic analysis, structural visualization and molecular 
modeling was used to begin a structure-activity relationship study.  
 
First, we targeted different active-site residues (PhD student Jordan Volpato) and 
we mutated them, generally by saturation mutagenesis. Different combinatorial libraries 
(mutagenesis at multiple sites) were also created in the laboratory, of which only library 
31/34/35 created by Jordan Volpato was described in chapter 2.  
Then, we developed an efficient two-tier bacterial and in vitro selection strategy 
to identify mutants presenting the phenotypes of interest: activity (DHF binding) and 
antifolate resistance (reduced enzyme inhibition). Following the screening, we obtained 
new functional information regarding the targeted residues, which was the goal of the 
proposed work. Position 115 is relatively permissive to mutations that conserve activity. 
All substitutions were hydrophobic (Ile, Leu, Ala, Tyr, Phe, Met) or had no H-bonding 
capacity (Cys). This feature appears to be required to preserve the activity. Novel MTX-
resistant mutants V115A and V115C were identified. The reduced hydrophobic contact 
surface of Ala and Cys appears to a have a greater impact on the MTX binding (= 
resistance) than on the DHF binding (= maintenance of activity), and therefore confers 
ligand discrimination. Due to its permissivity (many mutations are accepted), residue 115 
is surely an interesting candidate for further studies in a combinatorial context.  In the 
case of Ile7, only highly conservative mutations I7L and I7V preserved activity, 
highlighting the importance of hydrophobicity at this position. No substitutions were 
compatible with activity at position 70. Mutants may have been inactive, poorly 
expressed or unstable. Arg70 is highly conserved across species and was not permissive 
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to mutations; thus, it is likely required for the substrate binding, the structure or both. For 
this reason, it will not be mutated in complex libraries. 
We extended the utility of the screening method to identify further phenotypes of 
interest, like the resistance of mutant hDHFR to other antifolates. To be detected as 
inhibitor-resistant, a hDHFR mutant has to preserve a certain degree of catalytic activity. 
Therefore, in principle, every new antifolate can be tested in vitro towards any identified 
active mutant, as long as the molecule is soluble in the assay conditions. The results for 
PMTX resistance correlated with the ones for MTX-resistance, the only two PMTX-
resistant mutants identified being V115A and V115C. However, while mutation V115A 
reduced KiMTX 600-fold and affected productive binding of both PMTX and DHF in a 
similar fashion (200-fold decrease effect on KiPMTX and KMDHF, respectively), mutation 
V115C reduced KMDHF only 100-fold but KiMTX and KiPMTX of about 600-fold. Therefore, 
independently of the orientation of the PMTX pterin ring, for which structural data is not 
available, it appears that residue 115 can effectively offer some degree of ligand 
discrimination. Variants that are mutated at other active site positions will be screened 
against PMTX to verify the occurrence of ligand discrimination at specific areas. 
We have begun to build a SAR (Structure-Activity Relationship) with MTX, by 
investigating the binding of its constituent fragments DAP, p-ABA-Glu and DAMPA. 
Preliminary tests confirmed that, of the three tested fragments, only DAMPA efficiently 
inhibits WT hDHFR.  The lack of the L-glutamate portion of MTX accounted for a 65-
fold reduced inhibition (KiDAMPA/KiMTX for WT hDHFR). Mutation of residue 115 
(V115A), which is located far from the glutamate tail of the bound MTX, unexpectedly 
affected the binding of DAMPA, showing the importance of distal effects that cannot be 
visualized from the structure. Characterization of the double mutant F31R/Q35E (RFE) 
and of its constituent point mutants showed unpredictable synergistic contribution to the 
binding in the double mutant  
Finally, we performed in silico mutagenesis coupled with energy minimization to 
compare the predicted structure of the highly MTX-resistant triple mutant 
F31A/F34V/Q35H (AVH) to the native enzyme. Modeling suggested that an increased 
cavity volume lies at the root of the weakened ligand binding. The method is simple and 
allows postulating of reasonable structural hypothesis by correlating structural 
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visualization and kinetic/inhibitory parameters. We also used an automated docking 
approach to predict the binding of DHF and PMTX, for which structural data are not 
available. Although this remains a possible tool to test the inhibitory potential of a 
molecule, it is probably not precise enough for SAR studies.  
Currently, we are attempting to obtain a crystal structure of WT hDHFR 
complexed with PMTX (Jordan Volpato and Mirja Krause) to observe the orientation of 
its pyrrolo-pyrimidine moiety in the active site, information for which the current 
modeling results are contradictory.     
In conclusion, we developed an efficient approach to identify active and 
antifolate- resistant mutants of hDHFR and we have begun collecting structure-function 
information that will contribute to the development of highly specific drugs for this 
enzyme. Combinatorial libraries which target different areas of the active site and 
different antifolates will be screened and characterized in order to build a molecular map 
of the determinants of the ligand binding in the hDHFR active site. A BioMek bench-top 
robotic liquid-handler will be installed in the laboratory, allowing a larger number of 
variants to be characterized and a larger number of variables (substrate and inhibitor 
concentrations) to be examined. Kinetic characterization for inhibitor fragments and 
structural characterization both by X-ray crystallography and by modeling will be used as 
principal tools to reach the ultimate goal of a better understanding of the ligand binding. 
As complementary approach, STD-NMR (saturation transfer difference NMR)[125, 126], 
a NMR technique that allows the identification of the proximity of ligand atoms to the 
protein surface,  should also be considered as a tool for SAR studies.  
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